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A B S T R A C T
Background
Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but
the trade-off between safety and efficacy of primary thromboprophylaxis in cancer patients treated with chemotherapy is uncertain.
This is the second update of a review first published in February 2012.
Objectives
To assess the efficacy and safety of primary thromboprophylaxis for VTE in ambulatory cancer patients receiving chemotherapy
compared with placebo or no thromboprophylaxis.
Search methods
For this update the Cochrane Vascular Information Specialist searched the Cochrane Vascular Group Specialised Register (June 2016).
In addition, the Information Specialist searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 5).
Clinical trials registries were searched up to June 2016.
Selection criteria
Randomised controlled trials comparing any oral or parenteral anticoagulant or mechanical intervention to no thromboprophylaxis or
placebo, or comparing two different anticoagulants.
Data collection and analysis
We extracted data on methodological quality, participant characteristics, interventions, and outcomes including symptomatic VTE and
major bleeding as the primary effectiveness and safety outcomes, respectively.
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Main results
We identified five additional randomised controlled trials (2491 participants) in the updated search, considering in this update 26
trials with a total of 12,352 participants, all evaluating pharmacological interventions and performed mainly in people with locally
advanced or metastatic cancer. The quality of the evidence ranged from high to very low across the different outcomes and comparisons.
The main limiting factors were imprecision and risk of bias. One large trial of 3212 participants found a 64% (risk ratio (RR) 0.36,
95% confidence interval (CI) 0.22 to 0.60) reduction of symptomatic VTE with the ultra-low molecular weight heparin (uLMWH)
semuloparin relative to placebo, with no apparent difference in major bleeding (RR 1.05, 95% CI 0.55 to 2.00). When compared
with no thromboprophylaxis, LMWH significantly reduced the incidence of symptomatic VTE (RR 0.54, 95% CI 0.38 to 0.75; no
heterogeneity, Tau2 = 0.00%) with a non-statistically significant 44% higher risk of major bleeding events (RR 1.44, 95% CI 0.98
to 2.11). In participants with multiple myeloma, LMWH was associated with a significant reduction in symptomatic VTE compared
with the vitamin K antagonist warfarin (RR 0.33, 95% CI 0.14 to 0.83), while the difference between LMWH and aspirin was
not statistically significant (RR 0.51, 95% CI 0.22 to 1.17). Major bleeding was observed in none of the participants treated with
LMWH or warfarin and in less than 1% of those treated with aspirin. Only one study evaluated unfractionated heparin against no
thromboprophylaxis but did not report on VTE or major bleeding. When compared with placebo, warfarin was associated with a
non-statistically significant reduction of symptomatic VTE (RR 0.15, 95% CI 0.02 to 1.20). Antithrombin, evaluated in one study
involving paediatric patients, had no significant effect on VTE or on major bleeding when compared with no antithrombin. The direct
oral factor Xa inhibitor apixaban was evaluated in a phase II dose-finding study that suggested a low rate of major bleeding (2.1%
versus 3.4%) and symptomatic VTE (1.1% versus 13.8%) in comparison with placebo.
Authors’ conclusions
In this second update, we confirmed that primary thromboprophylaxis with LMWH significantly reduced the incidence of symptomatic
VTE in ambulatory cancer patients treated with chemotherapy. In addition, the uLMWH semuloparin, which is not commercially
available, significantly reduced the incidence of symptomatic VTE. The risk of major bleeding associated with LMWH, while not
reaching statistical significance, suggest caution and mandate additional studies to determine the risk-to-benefit ratio of LMWH in
this setting. Despite the encouraging results of this review, routine prophylaxis in ambulatory cancer patients cannot be recommended
before safety issues are adequately addressed. We need additional studies investigating targeted primary prophylaxis in people with
specific types or stages of cancer associated with a higher risk of VTE.
P L A I N L A N G U A G E S U M M A R Y
Prevention of blood clots in non-hospitalised cancer patients receiving chemotherapy
Background
Cancer patients are more likely than people without cancer to develop blood clots in their veins (known as venous thromboembolism).
Chemotherapy further increases this risk. Yet a number of factors specific to the cancer, such as the bleeding tendency at the site of
the cancer, or a relative decrease in the number of platelets in the blood (thrombocytopenia) caused by chemotherapy can increase the
likelihood that cancer patients will have bleeding complications with medicines used to prevent and treat blood clots (anticoagulants).
This systematic review looked at the effectiveness and safety of anticoagulants when used to prevent blood clots in cancer patients
receiving chemotherapy.
Key results
We included 26 randomised controlled trials involving a total of 12,352 participants (current until June 2016). Low molecular weight
heparin and the ultra-low molecular weight heparin semuloparin were associated with a significant reduction in symptomatic blood
clots. We found no evidence that the risk of major bleeding is increased with semuloparin or low molecular weight heparin, but based
on the uncertainty around the estimates, we cannot exclude that the risk is doubled. There was no clear survival benefit for semuloparin
or low molecular weight heparin. In people with multiple myeloma, low molecular weight heparin significantly reduced the incidence
of blood clots when compared with the vitamin K antagonist warfarin, while the difference with aspirin was not significant. There were
no major bleeds with low molecular weight heparin or warfarin, and in participants treated with aspirin the rate was below 1%. One
study evaluated unfractionated heparin and did not report on venous thromboembolism or major bleeding. There was no mention of
blood clots in the two study groups. Data for warfarin in comparison with placebo were too limited to support the use of warfarin
in the prevention of blood clots in cancer patients. One study in children evaluated antithrombin, which had no significant effect on
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blood clots or major bleeding when compared with no antithrombin. A small pilot study evaluated the oral anticoagulant apixaban
and found a low rate of bleeding and blood clots compared to placebo.
Quality of the evidence
The quality of the included studies ranged from low to high, such that future studies may change our confidence in the estimates and the
size of the estimates, in particular with regard to the safety of anticoagulants. The quality of findings ranged from high to very low across
the different outcomes and comparisons. The main limiting factors, which were the reason for a decrease in quality in some outcomes,
were imprecision and risk of bias. The relatively low number of studies, participants, and clinical events prevented us from determining
the potential influence of age and type or stage of cancer on treatment effects and providing more definitive conclusions about the
risk of bleeding in association with anticoagulants. None of the studies tested intermittent pneumatic compression or graduated elastic
stockings for the prevention of venous thromboembolism.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Semuloparin compared with placebo for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: semuloparin
Comparison: placebo
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
Without
semuloparin
With semuloparin
Symptomatic VTE:
Follow-up: median
3.5 months
RR 0.36 (0.22 to 0.
60)
Intermediate- risk population3 22 per 1000 fewer
events (14 to 27
fewer)
3212 (1) ⊕⊕⊕⊕
high
Semuloparin
decreases the in-
cidence of symp-
tomatic VTE across
dif ferent cancer
types
34 per 1000 12 per 1000
(8 to 21)
M ajor bleeding
Follow-up: median
3.5 months
RR 1.05 (0.55 to 2.
0)
Intermediate- risk population3 1 per 1000 more
events (5 fewer to 11
more)
3172 (1) ⊕⊕©©
low4
Semuloparin may in-
crease major bleed-
ings across dif fer-
ent cancer types11 per 1000 12 per 1000
(6 to 23)
Symptomatic PE
Follow-up: median
3.5 months
RR 0.48 (0.22 to 1.
01)
Intermediate- risk population3 7 per 1000 fewer
events (0 to 10
fewer)
3212 (1) ⊕⊕⊕©
moderate5
Semuloparin proba-
bly decreases the
incidence of symp-
tomatic
PE across dif ferent
cancer types
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13 per 1000 6 per 1000
(3 to 13)
Symptomatic DVT
Follow-up: median
3.5 months
RR 0.32 (0.16 to 0.
63)
Intermediate- risk population3 14 per 1000 fewer
events (8 to 18
fewer)
3212 (1) ⊕⊕⊕⊕
high
Semuloparin
decreases the in-
cidence of symp-
tomatic DVT across
dif ferent cancer
types
21 per 1000 7 per 1000
(3 to 13)
1-year mortality
Follow-up: 1 year
RR 1.02 (0.96 to 1.
08)
Intermediate- risk population3 11 per 1000 more
events (22 fewer to
44 more)
3212 (1) ⊕⊕⊕©
moderate5
Semuloparin proba-
bly has no ef fect
on 1-year mortal-
ity across dif ferent
cancer types
555 per 1000 566 per 1000
(533 to 599)
Clinically relevant
bleeding
Follow-up: median
3.5 months
RR 1.40 (0.90 to 2.
19)
Intermediate- risk population3 8 per 1000 more
events (2 fewer to 24
more)
3172 (1) ⊕⊕⊕©
moderate5
Semuloparin proba-
bly increases the
incidence of clini-
cally relevant bleed-
ing across dif ferent
cancer types
20 per 1000 28 per 1000
(18 to 44)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT : deep vein thrombosis; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the medium observed control group risk in the study.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3Intermediate risk populat ion refers to the observed median risk to experience symptomatic VTE in the single trial contribut ing
to the analyses (34 per 1000). Rates between 2% and 7% are considered intermediate risk (Khorana 2008).
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4Downgraded (2 levels) because of imprecision.
5Downgraded (1 level) because of imprecision.
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B A C K G R O U N D
Cancer is often complicated by venous thromboembolism (VTE),
which can present as deep vein thrombosis (DVT) or pulmonary
embolism (PE), or both (Khorana 2009). Cancer patients with
VTE have a two-fold or greater increasedmortality compared with
cancer patients without thrombosis, which could be explained by
the development of fatal PEs or by a worse prognosis for patients
with those cancers complicated by VTE (Sorensen 2000). VTE in
cancer patients may be hard to recognise due to aspecific symp-
toms, which may overlap and be confused with symptoms caused
by the underlying cancer disease process or cancer treatments.
VTE carries significant morbidity due to the need for hospitalisa-
tion and an increased risk of recurrent VTE or bleeding compli-
cations while on anticoagulation (Hutten 2000; Prandoni 2002).
The occurrence of symptomatic or unsuspected VTE may delay
the delivery of cancer treatments such as chemotherapy, with a
further negative impact on morbidity and potentially mortality. In
addition, the occurrence of venous thromboembolic events brings
further emotional strain for patients and their families, which neg-
atively impacts their quality of life. Finally, the costs related to
the management of VTE may be considerable, resulting from the
expenses related to the drugs and hospitalisation (Heit 2015).
Description of the condition
The incidence of VTE is higher in people with cancer compared
with people without cancer (Heit 2015). Compared with an inci-
dence of about 0.1% in the general population, the rate of VTE
in people with cancer has been reported to vary between 0.6%
and about 8% (Khorana 2009). Chemotherapy has been recog-
nised as an independent predictor for symptomatic VTE, with
reported rates of from 11%, in Otten 2004, up to 75%, in Heit
2015 and Khorana 2009, depending on the type of chemother-
apeutic agent used. The risk of thrombosis in cancer patients re-
ceiving chemotherapy seems to vary based on the stage of the dis-
ease, ranging from 3% to 5% in patients with early-stage cancer to
30% in those with metastatic or advanced malignancy (Khorana
2009). The benefit-risk ratio of primary prophylaxis in ambula-
tory patients with cancer who are receiving chemotherapy is not
well established, and current guidelines do not recommend rou-
tine thromboprophylaxis in such patients (Lyman 2013).
Description of the intervention
Currently available drugs for the prevention of VTE are the
parenteral anticoagulants, which include unfractionated heparin
(UFH), low molecular weight heparins (LMWH), and fonda-
parinux, vitamin K antagonists (VKAs), and the oral direct throm-
bin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban,
apixaban, and edoxaban. In fact, each one of these agents may
present disadvantages for long-termprophylaxis in the ambulatory
patient with cancer. Heparins and fondaparinux, as well as the
new ultra-lowmolecular weight heparin (uLMWH) semuloparin,
require daily subcutaneous injections, which represent a consid-
erable burden for the patient. Of note is that marketing applica-
tions for the uLMWH semuloparin have been withdrawn world-
wide, and it is therefore unlikely to ever be commercially avail-
able (EMEA 2012). Both the direct thrombin inhibitor dabiga-
tran and the factor Xa inhibitors offer the potential advantages of
an oral route of administration, and in comparison with VKAs do
not require routine laboratory monitoring and have fewer phar-
macological interactions. VKAs and direct thrombin or factor Xa
inhibitors can be difficult to administer in cancer patients with
nausea or vomiting.
The use of pharmacological prophylaxis may be more challenging
in people with cancer. The efficacy of pharmacological thrombo-
prophylaxis could be reduced by the intrinsic procoagulant state
induced by the cancer itself, prothrombotic treatments for cancer
(e.g. chemotherapy), as well as the decline in the patient’s general
condition leading to immobilisation. On the other hand, the risk
of bleeding events could be high even with prophylactic doses be-
cause of a number of predisposing factors such as the bleeding ten-
dency at the site of the cancer, the relative decrease in the number
of platelets in the blood (thrombocytopenia) secondary to chemo-
therapy, and the concomitant use of drugs (e.g. bevacizumab) that
affect the vessel wall integrity (Kamphuisen 2014).
Currently available mechanical interventions for the prevention of
VTE include intermittent pneumatic compression and graduated
elastic stockings. These non-pharmacological interventions may
be a valid option in cancer patients who are at risk of bleeding,
however evidence supporting their benefit and assuring no harm
is limited.
Why it is important to do this review
The overall burden of VTE in people with cancer is steadily in-
creasing as a result of an aging population, greater awareness, fre-
quent staging assessments using sensitive imaging techniques, pro-
thrombotic anticancer treatments, as well as the growing cancer
population that is due to the aforementioned aging (Heit 2015).
Provision of widespread primary thromboprophylaxis for ambu-
latory cancer patients who receive chemotherapy may help in pre-
venting this complication. However, the efficacy of thrombopro-
phylaxis needs to be balanced against the risks, such as (major)
bleeding events.
O B J E C T I V E S
Ourmain objective was to assess the efficacy and safety of primary
thromboprophylaxis for VTE in ambulatory patients with cancer
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receiving chemotherapy compared with placebo or no thrombo-
prophylaxis. The secondary objective was to compare the efficacy
and safety of different types of primary thromboprophylaxis by
stratifying the main results per type of drug or mechanical inter-
vention, and by aggregating results from head-to-head compar-
isons.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-randomised
trials were eligible.
Types of participants
Ambulatory outpatients at the time of randomisation or study
entry. Participants of any age (including paediatric patients) with
either a solid or haematological cancer, at any stage, and receiv-
ing chemotherapy were eligible. We excluded studies of partici-
pants receiving anticoagulation for a previous VTE or an indica-
tion other than VTE if data could not be extracted separately for
participants not on anticoagulants.We excluded studies evaluating
prophylaxis for catheter-related thrombosis, since this is already
the subject of another Cochrane review (Akl 2011).
Types of interventions
Interventions included any oral or parenteral anticoagulant (for
example UFH, LMWH, uLMWH, fondaparinux, direct throm-
bin or factor Xa inhibitors, VKAs) or mechanical intervention (in-
termittent pneumatic compression or graduated elastic stockings),
or both, used to prevent VTE in ambulatory patients with cancer
that were receiving chemotherapy. Comparison interventions in-
cluded either no thromboprophylaxis in the form of an inactive
control intervention (placebo, no treatment, standard care) or an
active control intervention (a different scheme or regimen of the
same intervention, a different pharmacological type of prophy-
laxis, a different type of non-pharmacological prophylaxis). We
considered any frequency or duration of administration, dosage or
intensity, and timing of delivery of pharmacological prophylaxis.
Types of outcome measures
Primary outcomes
The main effectiveness outcome was symptomatic VTE, objec-
tively verified by means of Doppler (compression) ultrasonogra-
phy or venography for DVT, and spiral computed tomography,
ventilation/perfusion lung scan, or pulmonary angiography for
PE.
The main safety outcome was major bleeding, typically defined as
overt bleeding associated with a fall in haemoglobin of 2 g/dL or
more, or leading to a transfusion of two ormore units of packed red
blood cells or whole blood; bleeding that occurred at a critical site
(intracranial, intraspinal, intraocular, pericardial, intra-articular,
intramuscular with compartment syndrome, retroperitoneal); or
bleeding contributing to death (Schulman 2005).
Secondary outcomes
Secondary outcomes included symptomatic PE; symptomatic
DVT; unsuspected (incidental) VTE; overall (symptomatic and
unsuspected) VTE; clinically relevant bleeding (major and clini-
cally relevant non-major bleeding);minor bleeding; one-year over-
all mortality; arterial thromboembolic events; superficial venous
thrombosis; quality of life; and number of participants experi-
encing any serious adverse event. Clinically relevant non-major
bleeding is typically defined as overt bleeding that does not meet
the criteria for major bleeding, but is associated with the need for
medical intervention, contact with a physician, or interruption
of the study drug or with discomfort or impairment of activities
of daily life. Minor bleeding was defined as a bleeding event not
matching the criteria for major bleeding or clinically relevant non-
major bleeding. Serious adverse events were defined as events re-
sulting in patient hospitalisation, prolongation of hospitalisation,
persistent or significant disability, congenital abnormality or birth
defect of offspring, life-threatening events or death. For trials using
LMWH as the intervention or control, heparin-induced throm-
bocytopenia (HIT) and the incidence of osteoporosis, as defined
by the trial authors, were recorded. We considered all outcomes as
binary outcomes except for quality of life, which we considered a
continuous outcome.
For the ’Summary of findings’ tables, we selected the following
outcomes as the most patient-relevant ones:
1. symptomatic VTE;
2. major bleeding;
3. symptomatic PE;
4. symptomatic DVT;
5. one-year mortality;
6. clinically relevant bleeding.
Search methods for identification of studies
Electronic searches
For this update, the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials:
• Cochrane Vascular Specialised Register (23 June 2016);
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• Cochrane Central Register of Controlled Trials
(CENTRAL) (2016, Issue 5) via the Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINEOvid, EmbaseOvid, CINAHL, AMED, and through hand-
searching relevant journals. The full list of the databases, journals
and conference proceedings which have been searched, as well as
the search strategies used are described in the Specialised Register
section of the Cochrane Vascular module in the Cochrane Library
(www.cochranelibrary.com).
The CIS searched the following clinical trials registries (last
searched 23 June 2016) by combining the search terms ’cancer’
and ’thrombosis’:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch);
• ISRCTN Register (www.isrctn.com/).
Searching other resources
The review authors searched the reference lists of identified studies
and contacted content experts and trialists for relevant references.
One review author screened the conference proceedings of the
American Society of Clinical Oncology (from 2009 to 2015) and
the International Society of Thrombosis and Haemostasis (from
2003 to 2016), combining the search terms of ’venous thrombo-
sis’, ’vein thrombosis’, or ’pulmonary embolism’ with ’cancer’ or
’tumour’. We included studies if we could obtain adequate infor-
mation from either the abstract or personal communication.
Data collection and analysis
Selection of studies
Two review authors (MDN, MC) independently reviewed the ti-
tles and abstracts identified from the database searches to deter-
mine whether they met the inclusion criteria. Any disagreements
were resolved through discussion between the review authors. The
review authors were not blinded to the journal, institution, or
results of the study. We applied no language restrictions. We re-
assessed studies with insufficient information if we were able to
obtain additional information from the trial authors. We docu-
mented reasons for excluding studies. In the event of multiple re-
ports relating to the same trial, we considered all of the reports.
Data extraction and management
Two review authors (MDN, MC) independently extracted the
data from the included studies onto standardised forms, resolving
any disagreements by consensus or by involving a third review
author (AR). We collected information on methodological qual-
ity, participant characteristics, characteristics of the intervention
and control groups, and outcome characteristics of every group of
participants. Whenever possible, we extracted the results from an
intention-to-treat analysis. If we could not calculate effect sizes,
we contacted the trial authors for additional data.
Assessment of risk of bias in included studies
Two review authors independently assessed randomisation, blind-
ing, and adequacy of analyses (Higgins 2011; Rutjes 2009). Dis-
agreements were resolved by consensus.
We assessed two components of randomisation: generation of al-
location sequence and concealment of allocation. We considered
generation of the allocation sequence to be adequate if it resulted
in an unpredictable allocation schedule. Mechanisms considered
to be adequate included random number tables, computer-gener-
ated randomnumbers,minimisation, coin tossing, shuffling cards,
and drawing lots. We considered trials using an unpredictable al-
location sequence to be randomised. We considered trials using
potentially predictable allocation mechanisms, such as alternation
or allocation of participants according to date of birth, date of
presentation, or case record number, to be quasi-randomised.
We considered concealment of allocation to be adequate if par-
ticipants and the investigators responsible for participant selec-
tion were unable to predict before allocation which treatment
was next.Methods considered adequate included central randomi-
sation; pharmacy-controlled randomisation using identical, pre-
numbered containers; and sequentially numbered, sealed, opaque
envelopes. We considered blinding of participants and therapists
to be adequate if experimental and control preparations were ex-
plicitly described as indistinguishable, or if a double-dummy tech-
nique was used. We considered assessors to be blinded if this was
explicitly mentioned by the investigators.
We considered analyses to be at low risk of bias if all randomised
participants were included in the analyses according to the inten-
tion-to-treat principle. We classified the item ’free of selective re-
porting’ as at low risk of bias if we had both the protocol and the
full report of a given study, where the full report presented results
for all outcomes listed in the protocol. We classified a study as at
high risk of bias if a report did not present data on all outcomes
reported in either the protocol or the methods section. We did not
consider the item ’free of other bias’ in this review. We assessed the
reporting of primary outcomes and sample size calculations. Fi-
nally, we used GRADE to describe the quality of the overall body
of evidence (Guyatt 2008; Higgins 2011), defined as the extent of
our confidence in the estimates of treatment benefits and harms.
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Measures of treatment effect
We have presented results as summary risk ratios (RRs) for di-
chotomous variables, determining a 95% confidence interval (CI)
for each estimate. We used inverse-variance random-effects model
meta-analysis to combine the trials (DerSimonian 1986). In the
case of statistically significant overall estimates, we also calculated
clinical effect summary statistics such as the number needed to
treat for an additional beneficial outcome (NNTB) or the number
needed to treat for an additional harmful outcome (NNTH) to
express the final results of the review.
Assessment of heterogeneity
We measured heterogeneity of the treatment effect between trials
using the variance estimate Tau2, as currently recommended by
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). A Tau2 of 0.04 is typically interpreted to indicate
low heterogeneity, 0.09 moderate heterogeneity, and 0.16 high
heterogeneity across trials (Rutjes 2012; Spiegelhalter 2004).
Assessment of reporting biases
We evaluated publication bias and other biases related to small
study size using funnel plots, plotting the RRs on the vertical axis
against their standard errors on the horizontal axis (Sterne 2001).
Funnel plot symmetrywould be expected in the absence of any bias
related to small study size. We used the Harbord-Egger’s test to as-
sess symmetry (Harbord 2006). We further explored any anomaly
in stratified analyses, in which we investigated the effects of dif-
ferences in types of LMWH, age, type of cancer, and suboptimal
design choices on the magnitude of the effects.
Data synthesis
In themain analyses, we analysed and presented data by stratifying
for the type of thromboprophylaxis used.
We planned to explore the between-trial heterogeneity by stratify-
ing the main outcomes for the following trial characteristics: age
(below or equal to 65 years versus above 65 years); type of cancer,
stage of cancer (metastatic versus non-metastatic); type of major
bleeding (according to the definition provided by Schulman 2005
versus unclear or different definition); concealment of allocation
(adequate versus inadequate or unclear); blinding (adequate versus
inadequate or unclear); analysis in accordance with the intention-
to-treat principle (yes versus no or unclear); trial size (large versus
small); and differences in the use of co-interventions in the trial
groups. We planned to use univariate random-effects model meta-
regression to determine whether treatment effects were affected
by these factors and by three continuous variables at trial level:
dosage of intervention, treatment duration, and length of follow-
up (Thompson 1999).
We defined large trials as those randomising 1360 participants or
more. This threshold was informed by the following sample size
calculation: according to the Khorana 2008 score, cancer patients
at high risk of symptomatic VTE who could potentially receive
thromboprophylaxis have an incidence of 7.1% over a period of
about 3 months. Assuming that the risk of VTE can be halved by
thromboprophylaxis, a total number of about 1360 participants
would be needed to detect a statistically significant difference be-
tween groups.
We performed the data analysis in Review Manager 5 (RevMan
2014). We performed stratified analyses and funnel plot explo-
ration in STATA release 14 (Stata 2015).
’Summary of findings’ table
Wepresented themain findings of the review concerning the qual-
ity of the evidence, magnitude of effect of the interventions exam-
ined, and sum of available data in a ’Summary of findings’ table,
according to the GRADE principles described by Higgins 2011
and Guyatt 2008. For the critical outcome symptomatic VTE, we
applied cutoffs to define high and intermediate risk groups. We
used a cutoff of 7% to define high risk, which is in line with the
cutoff proposed by Khorana 2008, which is between 6.7% and
7.1% over a period of about 3 months. We used event rates be-
tween 2% and 7% to define intermediate risk groups to experience
symptomatic VTEs (Khorana 2008).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Following title and abstract screening, we considered 27 re-
ports (21 trials) to be potentially eligible for this update. We
included eight reports related to five new trials (Elit 2012;
Khorana 2015; Lecumberri 2013; Macbeth 2016; Vadhan-Raj
2013), and 10 reports were related to previously included tri-
als. We added four reports to the Characteristics of ongoing
studies table (NCT00717938; NCT02048865; NCT02285738;
NCT02555878), and two to the Characteristics of studies
awaiting classification table (Ciftci 2012; NCT00771563). We
added two reports to the excluded studies (Bocharov 2011; Gercor
2013). We assessed one report that was a review as not relevant.
Included studies
For this update we included five new studies (Elit 2012; Khorana
2015; Lecumberri 2013; Macbeth 2016; Vadhan-Raj 2013). Four
of these were reported as ongoing studies in the previous version of
the review (Elit 2012; Khorana 2015;Macbeth 2016; Vadhan-Raj
2013), and one was an excluded study (Lecumberri 2013).
We added four additional ongoing studies (NCT00717938;
NCT02048865; NCT02285738; NCT02555878), and added
two additional studies to Studies awaiting classification (Ciftci
2012; NCT00771563).
In total, 26 RCTs randomising a total of 12,352 participants
were eligible for inclusion in the review. The treatments evaluated
consisted of the uLMWH semuloparin (Agnelli 2012), LMWH
(Agnelli 2009; Altinbas 2004; Elit 2012; Haas 2012; Kakkar
2004; Khorana 2015; Klerk 2005; Larocca 2012; Lecumberri
2013; Macbeth 2016; Maraveyas 2012; Palumbo 2011; Pelzer
2015; Perry 2010; Sideras 2006; Vadhan-Raj 2013; vanDoormaal
2011; Zwicker 2013), UFH (Lebeau 1994), the VKA warfarin
(Chahinian 1989; Levine 1994; Maurer 1997; Palumbo 2011;
Zacharski 1981), antithrombin (Mitchell 2003), and the oral di-
rect factor Xa inhibitor apixaban (Levine 2012). None of the
included RCTs used non-pharmacological prophylaxis, or phar-
macological thromboprophylaxis with fondaparinux, the direct
thrombin inhibitor dabigatran, or the direct factor Xa inhibitors
rivaroxaban and edoxaban. In 15 (8056 participants, 65%) of the
26 studies, inclusion was restricted to people with locally advanced
or metastatic cancer, in two studies limited cancer was included, in
four studies both early and advanced disease were included, while
in the remaining studies the stage was not clear (see Characteristics
of included studies).
One study assessed the uLMWH semuloparin versus placebo.
• Agnelli 2012 recruited participants (n = 3212) with
metastatic or locally advanced solid cancer of the lung, pancreas,
stomach, colon or rectum, bladder, or ovary and randomised
them to the uLMWH semuloparin (20 mg once daily) versus
placebo starting on the first day of a first or new regimen of
chemotherapy. The intervention was continued for three months
unless chemotherapy was stopped earlier.
Eigtheen studies assessed LMWH.
Sixteen studies assessedLMWHeither versus placeboor no throm-
boprophylaxis (Agnelli 2009; Altinbas 2004; Haas 2012; Kakkar
2004; Khorana 2015; Klerk 2005; Lecumberri 2013; Macbeth
2016; Maraveyas 2012; Pelzer 2015; Perry 2010; Sideras 2006;
Vadhan-Raj 2013; van Doormaal 2011; Zwicker 2013), or com-
pared different doses from prophylactic to full therapeutic of
LMWH with each other (Elit 2012). These 16 trials varied in
the duration and type of LMWH, including eight weeks to 48
months of subcutaneous (sc) dalteparin, enoxaparin, certoparin,
nadroparin, bemiparin. The dose of LMWH was prophylactic in
the majority of the studies and intermediate, in Pelzer 2015, or
therapeutic, in Maraveyas 2012, in one study each. In two stud-
ies initial therapeutic LMWHwas followed by intermediate doses
(Klerk 2005; van Doormaal 2011). Fifteen of these 16 studies re-
ported a mean age at study entry of 65 years or younger, whereas
Zwicker 2013 included participants with a mean age above 65.
• Agnelli 2009 recruited participants (n = 1150) with
metastatic or locally advanced lung, gastrointestinal, pancreatic,
breast, ovarian, or head and neck cancer and randomised them to
nadroparin (3800 IU anti-factor Xa sc, once daily) versus
placebo. Study treatment started on the same day as
chemotherapy and was given for the duration of the
chemotherapy or up to a maximum of 120 days (± 10 days).
• Altinbas 2004 recruited participants (n = 84) with
histologically confirmed small cell lung carcinoma and
randomised them to standard anticancer treatment with or
without dalteparin (5000 IU sc, once daily). Dalteparin was
stopped with disease progression or at the end of the 18 weeks of
chemotherapy.
• Elit 2012 recruited women (n = 77) with newly diagnosed
epithelial ovarian cancer and randomised them to receive
standard chemotherapy and one of three subcutaneous doses of
dalteparin (50 IU/kg, 100 IU/kg, or 150 IU/kg), once daily
during the first three of six cycles of three-weekly chemotherapy.
• Haas 2012 recruited participants with metastatic breast
cancer (n = 353) or non-small cell lung carcinoma (n = 547) and
receiving first- or second-line chemotherapy. Participants were
randomised to six months of certoparin (3000 IU sc, once daily)
versus placebo.
• Kakkar 2004 recruited participants (n = 385) with
histologically confirmed locally advanced or metastatic
malignant disease of the breast, lung, gastrointestinal tract,
pancreas, liver, genitourinary tract, ovary, or uterus and
randomised them to dalteparin (5000 IU sc, once daily) versus
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placebo. Study treatment was given for one year or until the
participant died, whichever occurred sooner.
• Khorana 2015 recruited cancer patients (n = 98) at high
risk for VTE (Khorana score ≥ 3) who initiated a new systemic
chemotherapy regimen and randomised them to dalteparin
(5000 IU sc, once daily) versus no thromboprophylaxis for 12
weeks.
• Klerk 2005 recruited participants (n = 302) with
metastasised or locally advanced solid tumours and randomised
them to nadroparin versus placebo. Study treatment was given
using pre-lled syringes containing a fixed volume of nadroparin
(anti-factor Xa 9500 U/mL) or placebo according to the
participant’s weight: 0.4 mL for those weighing less than 50 kg,
0.6 mL for those weighing between 50 kg and 70 kg, and 0.8 mL
for those weighing more than 70 kg. Study treatment was to be
administered sc twice daily during the initial 14 days of
treatment and once daily thereafter for another four weeks.
• Lecumberri 2013 recruited participants (n = 39) with newly
diagnosed, limited-stage small cell lung cancer and randomised
them to standard chemoradiotherapy alone or combined with
bemiparin 3500 IU daily for a maximum of 26 weeks.
• Macbeth 2016 recruited participants (n = 2202) with
histopathologic or cytologic diagnosis of primary bronchial
carcinoma of any stage and histology (small cell or non-small
cell) and randomised them to standard anticancer treatment
(including active supportive or palliative care) with or without
dalteparin (5000 IU sc, once daily) for a maximum of 24 weeks.
• Maraveyas 2012 recruited participants (n = 123) with
advanced pancreatic cancer and randomised them to dalteparin
(200 IU/kg sc, once daily for four weeks followed by 150 IU/kg
for a further eight weeks) in combination with gemcitabine
versus gemcitabine alone. Continuing dalteparin prophylaxis
after 12 weeks was not recommended, but was left to the
discretion of the investigator.
• Pelzer 2015 recruited participants (n = 312) with
histologically or cytologically confirmed advanced pancreatic
cancer. Participants were randomised to standard anticancer
treatment with or without enoxaparin (1 mg/kg once daily) for
three months, started simultaneously with palliative systemic
chemotherapy; after 12 weeks of initial chemotherapy, all
participants who had not progressed received the standard
therapy with or without enoxaparin (40 mg once daily) for an
additional three months.
• Perry 2010 recruited participants (n = 186) with newly
diagnosed, pathologically confirmed World Health Organization
(WHO) grade 3 or grade 4 glioma and randomised them to six
months of dalteparin (5000 IU sc, once daily) versus placebo
starting within the first month after surgery. Participants were
allowed to continue the study medication for 12 months.
• Sideras 2006 recruited participants (n = 138) with advanced
breast cancer who did not respond to first-line chemotherapy,
advanced prostate cancer resistant to primary hormonal therapy,
advanced lung cancer, or advanced colorectal cancer. In the first
part of the study, participants were randomised to dalteparin
(5000 IU sc, once daily) versus placebo, while in the second part
participants were randomised to dalteparin (5000 IU sc, once
daily) plus standard clinical care versus standard clinical care
alone. Dalteparin (or placebo) was given for 18 weeks or until
disease progression.
• Vadhan-Raj 2013 recruited participants (n = 75) with
advanced stage (unresectable or metastatic) adenocarcinoma of
the pancreas planning to initiate systemic chemotherapy and
randomised them to chemotherapy with or without dalteparin
(5000 IU sc, once daily) for 16 weeks.
• van Doormaal 2011 recruited participants (n = 503) with
non-small cell lung cancer (stage IIIB), hormone-refractory
prostate cancer, or locally advanced pancreatic cancer and
randomised them to standard anticancer treatment with or
without nadroparin. Subcutaneous nadroparin was administered
for six weeks (two weeks at therapeutic dose and four weeks at
half therapeutic dose). The participants were eligible to receive
additional cycles of nadroparin (two weeks at therapeutic dose
and four weeks washout period) for a maximum of six cycles.
• Zwicker 2013 recruited participants (n = 34) with
histologically confirmed advanced stage malignancy, which
included adenocarcinoma of the pancreas (locally advanced or
metastatic), colorectal (stage IV), non-small cell lung cancer
(stage III or IV), relapsed or stage IV ovarian, or surgically
unresectable or metastatic gastric adenocarcinoma. Participants
were randomised to enoxaparin (40 mg sc, once daily) for two
months or observation.
In two additional studies, LMWHwas compared against an active
control:
• Larocca 2012 recruited participants (n = 342) with newly
diagnosed multiple myeloma treated with lenalidomide and low-
dose dexamethasone induction and melphalan-prednisone-
lenalidomide consolidation. Participants were randomised to
aspirin (100 mg per day) or LMWH (enoxaparin 40 mg per
day). Prophylaxis was provided during the four (28-day) cycles of
induction and the six (28-day) cycles of consolidation therapy.
• Palumbo 2011 recruited participants (n = 667) with
previously untreated myeloma who received thalidomide-
containing regimens and randomised them to aspirin (100 mg
per day), low-dose warfarin (1.25 mg per day) or LMWH
(enoxaparin 40 mg per day). The prophylaxis was administered
during the three cycles of induction therapy in participants ≤ 65
years of age and during the first six cycles of induction therapy in
participants > 65 years.
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Four studies compared the VKAwarfarin against no thrombopro-
phylaxis or placebo.
• Chahinian 1989 recruited participants (n = 328) with
extensive carcinoma of the lung and randomised them to
warfarin (dose to maintain a prothrombin time 1.5 to twice the
control values) versus no warfarin. Warfarin was continued
throughout the course of chemotherapy.
• Levine 1994 recruited participants (n = 311) with
metastatic stage IV breast carcinoma who had been receiving
first- or second-line chemotherapy for four weeks or less and
randomised them to warfarin (target of international normalised
ratio (INR) 1.3 to 1.9) versus placebo. Study treatment began
either at the start of chemotherapy or within the following four
weeks and continued until one week after termination of
chemotherapy.
• Maurer 1997 recruited participants (n = 347) with limited-
stage small cell lung cancer who were to receive chemotherapy
and radiotherapy and randomised them to warfarin or no
warfarin. Warfarin (dose of 10 mg per day for the first three days
and then at a dose to maintain the prothrombin time between
1.4 and 1.6 times the local institutional control standards) was
continued through the complete course of chemotherapy and
radiation therapy and was stopped three weeks after the last cycle
of chemotherapy.
• Zacharski 1981 recruited participants (n = 50) with small
cell lung cancer and randomised them to warfarin (dose to
prolong the prothrombin time to approximately two times the
control value) versus no warfarin.
UFH, antithrombin, and the factor Xa inhibitor apixaban were
evaluated against placebo or no thromboprophylaxis in one study
each.
• Lebeau 1994 recruited participants (n = 277) with limited
and extensive small cell lung cancer who had not been previously
treated with chemotherapy or radiotherapy. The dose of UFH
was initially adapted to weight (500 IU/kg/day), then adjusted
by clotting times (different techniques used, and results had to
be between two and three times the control value). UFH was
administered in two or three daily injections for five weeks and
stopped one week after the second course of chemotherapy.
• Levine 2012 recruited participants (n = 125) receiving
either first- or second-line chemotherapy for advanced or
metastatic lung, breast, gastrointestinal, bladder, ovarian, or
prostate cancer; cancer of unknown origin; myeloma; or selected
lymphomas. Participants were randomised to apixaban 5 mg (n =
32), 10 mg (n = 30), 20 mg (n = 33), and placebo (n = 30). The
study treatment was given for 12 weeks, beginning within four
weeks of starting chemotherapy.
• Mitchell 2003 recruited paediatric patients (n = 85) newly
diagnosed with acute lymphoblastic leukaemia and randomised
them to receive, or not, weekly infusions of antithrombin.
Excluded studies
Weexcluded two additional studies in this update (Bocharov 2011;
Gercor 2013) making for a total of 24 excluded studies. The rea-
sons for exclusion were: design other than an RCT (Baz 2005;
Bocharov 2011; Kessler 2011; Meister 2008; Minnema 2004;
Paydas 2008; Zangari 2003); studies on perioperative throm-
boprophylaxis (Bergqvist 1983; Heilmann 1995; Hills 1972;
Macintyre 1974;Maxwell 2000; Sideras 2007;Welti 1981); inclu-
sion of hospitalised cancer patients (Eichinger 2008; Haas 2011;
Poniewierski 1987; Weber 2008); no relevant outcomes reported
(Rajan 1995); no eligible intervention (Niesvizky 2007); prophy-
laxis was for catheter-related thrombosis (Kwaan 2007). Three
studies were terminated early: Levin 2008 because of a drug sup-
ply issue; Gercor 2013 due to the lack of eligible patients; Pandya
2002 with no reason for study termination reported.
We added four studies to ongoing studies (NCT00717938;
NCT02048865; NCT02285738; NCT02555878).
Risk of bias in included studies
The ’Risk of bias’ summary is shown in Figure 2.
14Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The random sequence was adequately generated in 19 studies
(Agnelli 2009; Agnelli 2012; Chahinian 1989; Elit 2012; Haas
2012; Kakkar 2004; Klerk 2005; Larocca 2012; Lecumberri 2013;
Levine 1994; Levine 2012; Macbeth 2016; Maraveyas 2012;
Mitchell 2003; Palumbo 2011; Pelzer 2015; Perry 2010; van
Doormaal 2011; Zacharski 1981), but was unclear in the remain-
ing studies due to poor reporting.
Allocation was adequately concealed in 18 studies (Agnelli 2009;
Agnelli 2012; Elit 2012; Kakkar 2004; Klerk 2005; Larocca 2012;
Lebeau 1994; Lecumberri 2013; Levine 2012; Macbeth 2016;
Maraveyas 2012; Mitchell 2003; Palumbo 2011; Pelzer 2015;
Perry 2010; Sideras 2006; van Doormaal 2011; Zwicker 2013),
and was unclear in the remaining studies due to poor reporting.
Blinding
Eight studies had a double-blinded design (Agnelli 2009; Agnelli
2012; Haas 2012; Kakkar 2004; Klerk 2005; Levine 1994; Levine
2012; Perry 2010), and 14 were open studies (Altinbas 2004; Elit
2012; Larocca 2012; Lebeau 1994; Lecumberri 2013; Macbeth
2016; Maraveyas 2012; Mitchell 2003; Palumbo 2011; Pelzer
2015; Sideras 2006; Vadhan-Raj 2013; van Doormaal 2011;
Zwicker 2013). In four studies blindingwas unclear due to poor re-
porting (Chahinian 1989;Khorana 2015;Maurer 1997;Zacharski
1981).
Incomplete outcome data
Fourteen studies performed the analysis according to the in-
tention-to-treat principle (Agnelli 2012; Elit 2012; Khorana
2015; Klerk 2005; Larocca 2012; Lebeau 1994; Lecumberri
2013; Macbeth 2016; Maraveyas 2012; Pelzer 2015; Perry 2010;
Vadhan-Raj 2013; Zacharski 1981; Zwicker 2013), while in nine
studies the percentages of participants randomised and subse-
quently excluded from the analyses ranged from 1.3% to 10%
(Agnelli 2009; Chahinian 1989; Haas 2012; Kakkar 2004; Levine
1994; Levine 2012; Palumbo 2011; Sideras 2006; van Doormaal
2011); we considered these to be at high risk of bias. The study
involving paediatric patients used a per-protocol analysis and
excluded 22% of the participants that were initially enrolled
(Mitchell 2003); we considered this study to be at high risk of bias.
Attrition bias was unclear in Altinbas 2004 and Maurer 1997.
Selective reporting
We judged 18 studies to be free of selective reporting (Agnelli
2009; Agnelli 2012; Altinbas 2004; Elit 2012; Haas 2012; Kakkar
2004; Khorana 2015; Klerk 2005; Larocca 2012; Lebeau 1994;
Lecumberri 2013; Levine 1994; Levine 2012; Macbeth 2016;
Maraveyas 2012; Mitchell 2003; Sideras 2006; van Doormaal
2011). In four studies one or more outcomes that were reported
in the results were not anticipated in the methods sections of the
publications (Chahinian 1989; Maurer 1997; Vadhan-Raj 2013;
Zacharski 1981). In four studies not all outcomes were reported
in the results (Palumbo 2011; Pelzer 2015; Perry 2010; Zwicker
2013).
Effects of interventions
See: Summary of findings for the main comparison
Semuloparin versus placebo; Summary of findings 2 Low
molecular weight heparin versus no thromboprophylaxis;
Summary of findings 3 Prophylactic versus intermediate or
therapeutic dose low molecular weight heparin; Summary
of findings 4 Low molecular weight heparin versus aspirin;
Summary of findings 5 Low molecular weight heparin versus
vitamin K antagonists; Summary of findings 6 Unfractionated
heparin versus no thromboprophylaxis; Summary of findings 7
Vitamin K antagonists versus placebo or no thromboprophylaxis;
Summary of findings 8 Vitamin K antagonists versus aspirin;
Summary of findings 9 Antithrombin versus placebo; Summary
of findings 10 Apixaban versus placebo
Anticoagulants versus control
uLMWH versus placebo
Primary outcomes
In one large trial of 3212 participants (Agnelli 2012), semuloparin
was associated with a significant reduction in symptomatic VTE
(RR 0.36, 95% CI 0.22 to 0.60), corresponding to a NNTB of 46
(95% CI 31 to 87). There were 19/1589 major bleeding events in
the semuloparin group versus 18/1583 in the placebo group (RR
1.05, 95% CI 0.55 to 2.00). The quality of the evidence was high
for symptomatic VTE and low for major bleeding (see Summary
of findings for the main comparison).
In participants with lung and pancreatic cancers, semuloparin re-
duced symptomatic VTE by 64% (9/591 versus 25/589; RR 0.36,
95% CI 0.17 to 0.76) and by 78% (3/126 versus 14/128; RR
0.22, 95% CI 0.06 to 0.74), respectively. Rates of major bleeding
were not reported separately for these types of cancer.
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Secondary outcomes
The risk of symptomatic PE was reduced by 52% (RR 0.48, 95%
CI 0.22 to 1.01), and symptomatic DVT (RR 0.32, 95% CI 0.16
to 0.63) and overall VTE (RR 0.36, 95%CI 0.22 to 0.60) were re-
duced by about two-thirds with semuloparin.We foundmoderate-
quality evidence for symptomatic PE and high-quality evidence
for DVT (see Summary of findings for the main comparison).
Fatal PE occurred in 0.4% of participants on semuloparin and
0.6% of participants on placebo. Clinically relevant bleeding was
reported in 2.8% and 2.0%, respectively (RR 1.40, 95% CI 0.90
to 2.19). We judged the quality of the evidence for clinically rel-
evant bleeding as moderate. Semuloparin did not influence inci-
dental VTE (RR 0.14, 95% CI 0.01 to 2.76) or one-year mortal-
ity (RR 1.02, 95% CI 0.96 to 1.08; moderate-quality evidence).
The incidence of serious adverse events or thrombocytopenia was
similar in the semuloparin and placebo groups (26% versus 25%
and 7.1% versus 7.6%, respectively), with no cases of heparin-
induced thrombocytopenia (HIT).
LMWH versus placebo or no thromboprophylaxis
Primary outcomes
The clinical trials evaluating LMWHagainst placebo or no throm-
boprophylaxis varied in the duration and type of LMWH, includ-
ing 8 weeks to 48 months of subcutaneous dalteparin, enoxaparin,
certoparin, nadroparin, or bemiparin. The dose of LMWH was
prophylactic in the majority of the studies, and intermediate, in
Pelzer 2015, or therapeutic, inMaraveyas 2012, in one study each.
In two studies initial therapeutic LMWH was followed by inter-
mediate doses (Klerk 2005; van Doormaal 2011).
Based on pooled estimates from nine RCTs, LMWH, when com-
pared with no thromboprophylaxis, was associated with a signif-
icant reduction in symptomatic VTE (RR 0.54, 95% CI 0.38 to
0.75; 3284 participants) (Figure 3) in the absence of heterogeneity
(Tau2 = 0.00). This corresponded to aNNTBof 30 (95%CI 23 to
56), assuming a background risk of 71 symptomatic VTE events
per 1000 patients (Summary of findings 2) (Khorana 2008). Fun-
nel plot exploration did not show any evidence of biases associated
with small studies (Figure 4). Stratified analyses did not show any
effect of the type of LMWH, type of cancer, dosage, or design
characteristics on the relative risk of symptomatic VTE (Table 1).
Similarly, we found no evidence for a linear association between
treatment duration and the risk of symptomatic VTE using meta-
regression analysis (P = 0.514).
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Figure 3. Forest plot of comparison: 1 Anticoagulants versus control: symptomatic VTE, outcome: 1.2
Symptomatic VTE: LMWH versus no thromboprophylaxis.
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Figure 4. Funnel plot of comparison: 1 Anticoagulants versus control: symptomatic VTE, outcome: 1.2
Symptomatic VTE: LMWH versus no thromboprophylaxis.
The difference in major bleeding was not statistically significant
(RR 1.44, 95% CI 0.98 to 2.11; 6356 participants; 13 studies)
(Figure 5), in the absence of heterogeneity (Tau2 = 0.00). Vi-
sual examination of the funnel plot and Harbord-Egger’s test (P
= 0.881) did not show asymmetry (Figure 6), so that we did not
detect publication bias or other biases related to small study size.
The results of the stratified analyses, which did not show any ef-
fect of the type of LMWH, dosage, type of cancer, definition of
major bleeding, trial size, or design characteristics on the relative
risk of major bleeding, are presented in Table 2. Again, we found
no evidence for a linear association between treatment duration
and the risk of major bleeding using meta-regression analysis (P =
0.751).
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Figure 5. Forest plot of comparison: 2 Anticoagulants versus control: major bleeding, outcome: 2.2 Major
bleeding: LMWH versus no thromboprophylaxis.
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Figure 6. Funnel plot of comparison: 2 Anticoagulants versus control: major bleeding, outcome: 2.2 Major
bleeding: LMWH versus no thromboprophylaxis.
The quality of the evidence was high for symptomatic VTE and
low for major bleeding (see Summary of findings 2).
Secondary outcomes
There was a significant effect on symptomatic PE (RR 0.59, 95%
CI 0.40 to 0.86; 5226 participants; 7 studies; Tau2 = 0.00). This
corresponds to a NNTB of 174 (95% CI 119 to 510). Fatal PE
was reported by Macbeth 2016 in 0.3% of participants receiv-
ing LMWH and 0.5% of those receiving no thromboprophylaxis,
whereas Maraveyas 2012 reported 8% fatal VTEs in the group
receiving no thromboprophylaxis versus none in the dalteparin
group. In four studies no fatal VTEs were reported in any of the
study groups (Agnelli 2009; Elit 2012; Lecumberri 2013; Pelzer
2015). We judged the quality of the evidence for symptomatic
PE as low (see Summary of findings 2). The risk of symptomatic
DVT was reduced by 51% (RR 0.49, 95% CI 0.35 to 0.67; 5310
participants; 8 studies; Tau2 = 0.00), corresponding to a NNTB
of 68 (95% CI 53 to 105). We found high-quality evidence for
symptomatic DVT. Overall, VTE was reduced by 41% (RR 0.59,
95% CI 0.48 to 0.73; 5366 participants; 9 studies; Tau2 = 0.00),
corresponding to a NNTB of 25 (95% CI 20 to 38). There was
a significant increase in clinically relevant bleeding with LMWH
(RR 3.40, 95%CI 1.20 to 9.63; 3105 participants; 4 studies; Tau2
= 0.73; moderate-quality evidence). There was no statistically sig-
nificant benefit or harm for incidental VTE, minor bleeding, one-
year mortality, symptomatic arterial thromboembolism, superfi-
cial venous thrombosis, or serious adverse events (Data and anal-
yses). Only two studies evaluated quality of life through question-
naires (Macbeth 2016; Sideras 2006). Sideras 2006 found similar
results in participants randomised to LMWH or no thrombopro-
phylaxis, both at baseline and during the study period (Sideras
2006). Forty-four per cent and 51% of the participants, respec-
tively, reported decreased quality of life during the treatment pe-
riod by a clinically meaningful amount of 10 points on a 100-
point scale. Macbeth 2016 found no difference between LMWH
and no thromboprophylaxis with respect to quality-adjusted life
years gained in the first year and no difference in overall quality
of life at 6 months (P = 0.94) or 12 months (P = 0.89). Three
studies reported no cases of HIT with LMWH use (Haas 2012;
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Klerk 2005; Pelzer 2015). Haas 2012 reported objectively verified
skeletal events (including all fractures, spinal cord compressions,
and requirements for surgery to treat fractures or for bone irradi-
ation) in 16/442 and 19/441 of participants in the LMWH and
placebo groups, respectively.
Macbeth 2016 reported on compliance with LMWH. Of the
977 (89%) participants in whom compliance was evaluated, 180
(18.4%) were considered as fully compliant, whereas 431 (39%)
received half of the planned syringes or less.
Five studies reported on symptomatic VTE and major bleeding in
participantswith non-small cell lung cancer (Haas 2012), small cell
lung cancer (Altinbas 2004; Lecumberri 2013), or both (Agnelli
2009; Macbeth 2016). Pooled analysis of these trials showed a
significant 60%reduction in symptomaticVTE (RR0.40, 95%CI
0.20 to 0.80), whereas there was no statistically significant higher
risk of major bleeding with LMWH compared with the control
treatment (RR 1.49, 95% CI 0.79 to 2.80) and no evidence of
statistical heterogeneity (Tau2 = 0.00) (Table 1; Table 2).
Two studies reported on symptomatic VTE and major bleeding
in participants with advanced pancreatic cancer (Maraveyas 2012;
Pelzer 2015). Pooled analysis of these trials showed a significant
59% reduction in symptomatic VTE (RR 0.41, 95% CI 0.23 to
0.75) and no increase in major bleeding (RR 1.21, 95% CI 0.58
to 2.51) with LMWH and no evidence of statistical heterogene-
ity (Tau2 = 0.00) (Table 1; Table 2). Vadhan-Raj 2013 also selec-
tively included participants with advanced pancreatic cancer and
reported 2 DVTs in the dalteparin arm and 8 VTEs (2 PE and 6
DVT) in 37 participants receiving no thromboprophylaxis. The
abstract does not report whether these events were symptomatic,
incidental, or both. There were no clinically significant bleeding
events with dalteparin, although the definition of bleeding is not
provided and it is not reported if any bleeding occurred in partic-
ipants in the control group.
LMWH versus active control
Elit 2012 compared three doses of dalteparin against each other.
There were no symptomatic VTEs or major bleeding events dur-
ing dalteparin administration. Two participants developed symp-
tomatic VTE, and one was diagnosed with incidental PE after dal-
teparin discontinuation. The quality of the evidence was low for
symptomatic VTE and could not be evaluated for major bleeding
as the RR was not estimable due to zero count in all trial arms (see
Summary of findings 3). Three participants had minor bleeding
in the highest-dose group (150 IU/kg). There were no cases of
HIT. Compliance with injections was more than 80% in all three
dose groups.
In two studies of multiple myeloma patients receiving thalido-
mide- and lenalidomide-based regimens, LMWH was compared
against an active control, which in both studies was aspirin
(Larocca 2012; Palumbo 2011), and in one of the studies was VKA
(warfarin) (Palumbo 2011).When compared with aspirin, pooled
analysis showed a not statistically significant 49% reduction in
symptomatic VTE (RR 0.51, 95% CI 0.22 to 1.17; 781 partici-
pants; 2 studies). There were 3/396 major bleeding events with as-
pirin and none with LMWH (0/385). The quality of the evidence
was moderate for symptomatic VTE and low for major bleeding
(see Summary of findings 4). The incidence of symptomatic PE
was reduced by 87% (RR 0.13, 95% CI 0.02 to 1.03; 781 par-
ticipants; 2 studies; moderate-quality evidence), but the CIs were
wide and the estimate was not significant. Likewise, there were
no significant differences between LMWH and aspirin regarding
the incidence of symptomatic DVT (low-quality evidence), minor
bleeding, and symptomatic arterial thromboembolism.
In the study of Palumbo 2011, LMWHwas associated with a 67%
reduction in symptomaticVTE relative towarfarin (RR0.33, 95%
CI 0.14 to 0.83; 439 participants; high-quality evidence), with
no major bleeding events reported in either group. The pooled
estimates did not conclusively rule out an increase or reduction
in symptomatic PE (RR 0.11, 95% CI 0.01 to 2.06; low-quality
evidence) and symptomatic DVT (RR 0.43, 95%CI 0.17 to 1.10;
moderate-quality evidence). There were no differences between
LMWH and warfarin regarding the incidence of minor bleeding
and symptomatic arterial thromboembolism.
UFH versus no thromboprophylaxis
One studywith 277participants evaluatedUFHagainst no throm-
boprophylaxis (Lebeau 1994), and did not report on symptomatic
or incidental VTE or on major bleeding. Clinically relevant bleed-
ing occurred in 2/138 versus 1/139 of participants, respectively
(RR 2.01, 95% CI 0.18 to 21.96; P = 0.57; low-quality evidence).
The summary estimate did not conclusively rule out an increase
or reduction in 1-year mortality (RR 0.86, 95% CI 0.72 to 1.03;
moderate-quality evidence). There were no cases of HIT.
VKA versus placebo or no thromboprophylaxis
Levine 1994 (311 participants) reported an 85% reduction of
symptomatic VTE (RR 0.15, 95% CI 0.02 to 1.20) with warfarin
relative to placebo, albeit this finding was not statistically signifi-
cant. There was no significant effect on major bleeding (RR 0.52,
95% CI 0.05 to 5.71), symptomatic PE (RR 1.05, 95% CI 0.07
to 16.58), symptomatic DVT (RR 0.08, 95% CI 0.00 to 1.42), or
minor bleeding (RR 2.44, 95%CI 0.64 to 9.27). No symptomatic
arterial thromboembolic events were observed in either group.
Three studies reported major bleeding events (Chahinian 1989;
Maurer 1997; Zacharski 1981), but provided no data on the oc-
currence of symptomatic or incidental VTE. Pooled analysis of all
studies evaluating VKA versus placebo or no thromboprophylaxis
showed a non-statistically significant four-fold increase in major
bleeding (RR 3.82, 95%CI 0.97 to 15.04) with evidence of a high
degree of heterogeneity (Tau2 = 0.71).
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The quality of the evidence was low for symptomatic VTE, major
bleeding, and symptomatic DVT and very low for symptomatic
PE (see Summary of findings 7).
VKA versus active control
Palumbo 2011 reported a non-statistically significant difference
between VKA (warfarin) and aspirin with regard to symptomatic
VTE (RR 1.50, 95%CI 0.74 to 3.04; 440 participants; moderate-
quality evidence). There were 3 (3/220) major bleeding events in
the aspirin group and none (0/220) in the warfarin group (RR
0.14, 95%CI 0.01 to 2.75; P = 0.20; 440 participants; low-quality
evidence). Evidence did not conclusively show that VKA increased
or reduced the incidence of symptomatic PE or symptomaticDVT
(moderate-quality evidence) (Analysis 1.7; Analysis 2.7). There
were no differences for the other secondary outcomesminor bleed-
ing and symptomatic arterial thromboembolism (Palumbo 2011).
We refer to the previous section ’LMWH versus active control’ for
the description of the comparison of VKA versus LMWH.
Antithrombin versus no thromboprophylaxis
One study that recruited 85paediatric patients assessed antithrom-
bin (Mitchell 2003). The effects of antithrombin on major bleed-
ing (RR 0.78, 95% CI 0.03 to 18.57; very low-quality evidence)
and overall VTE (RR 0.84, 95% CI 0.41 to 1.73) were not statis-
tically significant. The remaining outcomes were not reported.
Factor Xa inhibitors versus placebo
In a phase II dose-finding study, Levine 2012 observed 0/32, 0/
29, 2/32, and 1/29 major bleeding events in the groups receiving
apixaban 5 mg, 10 mg, 20 mg, and placebo, respectively, for an
overall rate of major bleeding in the 93 apixaban participants of
2.1% versus 3.4% in the placebo group. There were 4 (13.8%)
symptomatic VTEs in the placebo group, while one participant
(1.1%) in the 20 mg apixaban group experienced a DVT of the
arm. We judged the quality of the evidence as moderate for symp-
tomatic VTE and low formajor bleeding (see Summary of findings
10). Two participants in the 5 mg and one in the 20 mg apixaban
groups (3.1%) experienced an adverse event, graded as 3 or higher,
which was possibly or probably related to treatment, compared
with none in the placebo group.
Evidence did not conclusively show that apixaban increased or
reduced the incidence of symptomatic PE (RR 0.11, 95% CI 0.00
to 2.54; low-quality evidence), but apixaban reduced the incidence
of symptomatic DVT (RR 0.08, 95% CI 0.01 to 0.67; moderate-
quality evidence).
There were six cases of clinically relevant bleeding among the 93
participants on apixaban versus 1 in 29 placebo recipients (RR
1.87, 95% CI 0.23 to 14.91; low-quality evidence).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Low molecular weight heparin compared with no thromboprophylaxis for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: LMWH
Comparison: no thromboprophylaxis (placebo or no LMWH)
Outcomes Relative effect (95%
CI)
Illustrative comparative risk (95% CI)* Difference (95% CI)
2
No of participants
(studies)
Quality of the evi-
dence (GRADE)
What it means
Assumed risk1 Corresponding risk
No thromboprophy-
laxis
With LM WH
Symptomatic VTE
Follow-up: median
10 months
RR 0.54 (0.38 to 0.
75)
High- risk population3 33 per 1000 fewer
events (18 to 44
fewer)
3284 (9) ⊕⊕⊕⊕
high4
LMWH decreases
the incidence of
symptomatic
VTE across dif ferent
cancer types
71 per 1000 39 per 1000
(27 to 54)
M ajor bleeding
Follow-up: median
12 months
RR 1.44 (0.98 to 2.
11)
High- risk population3 8 per 1000 more ma-
jor bleeds (0 to 19
more)
6356 (13) ⊕⊕©©
low5
LMWH may in-
crease major bleed-
ings across dif fer-
ent cancer types17 per 1000 25 per 1000
(17 to 36)
Symptomatic PE
Follow-up: median
10 months
RR 0.59 (0.40 to 0.
86)
High- risk population3 6 per 1000 fewer
events (2 to 8 fewer)
5226 (7) ⊕⊕©©
low6
LMWH may de-
crease the incidence
of symptomatic
PE across dif ferent
cancer types
14 per 1000 8 per 1000
(6 to 12)
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Symptomatic DVT
Follow-up: median
10 months
RR 0.49 (0.35 to 0.
67)
High- risk population3 15 per 1000 fewer
events (10 to 19
fewer)
5310 (8) ⊕⊕⊕⊕
high7
LMWH decreases
the incidence of
symptomatic
DVT across dif ferent
cancer types29 per 1000 14 per 1000
1-year mortality
Follow-up: median
12 months
RR 0.93 (0.80 to 1.
09)
High- risk population3 41 per 1000 fewer
deaths (117 fewer to
53 more)
2304 (8) ⊕⊕©©
low8
LMWH may de-
crease the incidence
of death across dif -
ferent cancer types587 per 1000 546 per 1000
(470 to 640)
Clinically relevant
bleeding
Follow-up: median
12 months
RR 3.40 (1.20 to 9.
63)
High- risk population3 40 per 1000 more
clinically relevant
bleeds (3 to 145
more)
3105 (4) ⊕⊕⊕©
moderate9
LMWH probably in-
creases the in-
cidence of clini-
cally relevant bleed-
ing across dif ferent
cancer types
17 per 1000 57 per 1000
(20 to 162)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT : deep vein thrombosis; LM WH: low molecular weight heparin; PE: pulmonary embolism; RR: risk rat io; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the median control group risk across the studies.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3High-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to the
analyses (71 per 1000). Rates f rom 7% and higher are considered high risk (Khorana 2008).
4Although 5 out of 9 trials were not double-blinded trials, and 2 out of 9 trials used dosages exceeding typical prophylact ic
dosages, results were consistent across trials, so we did not downgrade.
5Downgraded (2 levels) because the 95% CI includes both negligible ef fect and appreciable benef it or appreciable harm; 7
out of 12 trials contribut ing to the analyses were not double-blinded, and 3 out of 12 trials did not use standard def init ions to
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ascertain major bleeding. One study reported zero events in both the experimental and control arm, and was not considered
in the ’Summary of f indings’ table.
6Downgraded (2 levels) because the 95% CI includes both negligible ef fect and appreciable benef it or appreciable harm; risk
of select ive outcome report ing, with only 5 out of 7 trials report ing symptomatic PE.
7Although 4 out of 8 trials were not double-blinded trials, and 2 out of 8 trials used dosages exceeding typical prophylact ic
dosages, results were consistent across trials, so we did not downgrade.
8Downgraded (2 levels) because the 95% CI includes both negligible ef fect and appreciable benef it or harm; with some
variability in est imates across trials due to heterogeneity other than sampling error (chance).
9Downgraded (1 level) due to unexplained between-trial variat ion.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Low molecular weight heparin: prophylactic dose compared with intermediate or therapeutic dose for primary thromboprophylaxis in ambulatory cancer patients receiving
chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: prophylact ic dose LMWH
Comparison: intermediate or therapeut ic dose LMWH
Outcomes Control type Relative effect
(95% CI)
Illustrative comparative risks* (95%
CI)
Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding
risk
Intermediate/
therapeutic dose
Prophylactic dose
Intermediate- risk population3
Symptomatic
VTE:
Follow-up: me-
dian 3.5 months
Intermediate RR 2.89 (0.12 to
66.75)
31 per 1000 90 per 1000 (4 to
2086)
59 per 1000 more
events (28 fewer
to 2055 more)
51 (1) ⊕⊕©©
low4
Prophy-
lact ic-dose LMWH
may be associated
with a higher risk
of symptomatic
VTE when com-
pared to interme-
diate-dose LMWH
in ovarian cancer
Therapeut ic RR 1.00 (0.07 to
15.15)
53 per 1000 53 per 1000
(4 to 805)
0 per 1000 fewer
events (49 fewer
events to 752
more)
52 (1) ⊕⊕©©
low4
We do not know if
prophy-
lact ic-dose LMWH
is associated with
a higher risk
of symptomatic
2
7
P
rim
a
r
y
p
ro
p
h
y
la
x
is
fo
r
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
in
a
m
b
u
la
to
r
y
c
a
n
c
e
r
p
a
tie
n
ts
re
c
e
iv
in
g
c
h
e
m
o
th
e
ra
p
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
VTE when com-
pared to therapeu-
t ic-dose LMWH in
ovarian cancer
Intermediate- risk population3
M ajor bleeding
Follow-up: me-
dian 3.5 months
Intermediate Not est imable5 NA NA NA NA NA As we have in-
suf f icient data to
est imate the rel-
at ive risk, we
do not know
how prophylact ic-
dose LMWH af -
fects major bleed-
ing in ovarian can-
cerTherapeut ic Not est imable
5 NA NA NA NA NA
Intermediate- risk population3
Symptomatic PE
Follow-up: me-
dian 3.5 months
Intermediate RR 2.89 (0.12 to
66.75)
NA6 NA NA NA NA As we have insuf -
f icient data to est i-
mate the assumed
risk, we do not
know how prophy-
lact ic-dose LMWH
af fects
symptomatic PE
Therapeut ic RR 3.00 (0.13 to
70.42)
NA6 NA NA NA NA
Intermediate- risk population3
Symptomatic
DVT
Follow-up: me-
dian 3.5 months
Intermediate Not est imable5 NA NA NA NA NA We do not know
how prophylact ic-
dose LMWH af -
fects
symptomatic DVT
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Therapeut ic RR 0.33 (0.01 to 7.
82)
53 per 1000 18 per 1000
(1 to 415)
36 per 1000 fewer
DVT (53 fewer to
362 more)
52 (1) ⊕⊕©©
low4
Prophylact ic-
dose LMWH may
reduce the risk
of symptomatic
DVT when com-
pared to therapeu-
t ic-dose LMWH
in ovarian can-
cer, although this
seems an implau-
sible f inding
Intermediate- risk population3
1-year mortality
Follow-up: NA
Intermediate NA7 NA NA NA NA NA We do not know
how prophylact ic-
dose LMWH af -
fects
all-cause mortal-
ity when com-
pared to interme-
diate or therapeu-
t ic-dose LMWHTherapeut ic NA
7 NA NA NA NA NA
Intermediate- risk population3
Clinically rele-
vant bleeding
Follow-up: me-
dian 3.5 months
Intermediate NA5 NA NA NA NA NA We do not know
how prophylact ic-
dose LMWH af -
fects clinically rel-
evant bleeding
Therapeut ic RR 0.33 (0.01 to 7.
82)
38 per 10008 13 per 1000
(0 to 301)
26 per 1000 fewer
clinically relevant
bleeding (38 fewer
to 262 more)
52 (1) ⊕⊕©©
low4
Prophylact ic-dose
LMWH may reduce
clinically relevant
bleed-
ing when com-2
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pared to therapeu-
t ic-dose LMWH in
ovarian cancer
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; LM WH: low molecular weight heparin; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VTE: venous
thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the medium observed control group risk in Elit 2012 and Pelzer 2015 for the intermediate-
dose est imation, and f rom Elit 2012 and Maraveyas 2012 for therapeut ic-dose LMWH.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3Intermediate-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to
the analyses (31 per 1000 and 53 per 1000). Rates between 2% and 7% are considered intermediate risk (Khorana 2008).
4Downgraded (2 levels) because of imprecision.
5Not est imable due to zero event count in both trial arms.
6We have insuf f icient data to est imate the assumed risk due to the zero event rate in both the intermediate-dose and
therapeut ic-dose LMWH.
7No trials contributed to this outcome.
8The assumed risk was based on the small t rial by Elit 2012 only (the observed event rate in the control group was 1 out of
26).
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Low molecular weight heparin compared with aspirin for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: LMWH
Comparison: aspirin
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
Aspirin With LM WH
(any dosage)
Symptomatic VTE:
Follow-up: median
18.5 months
RR 0.51 (0.22 to 1.
17)
Intermediate- risk population3 19 per 1000 fewer
events (30 fewer to
7 more)
781 (2) ⊕⊕⊕©
moderate4
LMWH probably de-
creases the inci-
dence of symp-
tomatic VTE when
compared with as-
pirin in mult iple
myeloma
39 per 1000 20 per 1000
(9 to 45)
M ajor bleeding
Follow-up: median
18.5 months
RR 0.14 (0.01 to 2.
76)
Intermediate- risk population3 6 per 1000 fewer
events (7 fewer to 12
more)
781 (2) ⊕⊕©©
low5
LMWH may reduce
the incidence of ma-
jor bleeding when
compared with as-
pirin in mult iple
myeloma
7 per 1000 1 per 1000
(0 to 19)
Symptomatic PE
Follow-up: median
18.5 months
RR 0.13 (0.02 to 1.
03)
Intermediate- risk population3 15 per 1000 fewer
events (17 fewer to
1 more)
781 (2) ⊕⊕⊕©
moderate4
LMWH probably re-
duces the inci-
dence of symp-
tomatic PE when
compared with as-
pirin in mult iple
myeloma31
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18 per 1000 2 per 1000
(0 to 18)
Symptomatic DVT
Follow-up: median
18.5 months
RR 0.81 (0.32 to 2.
04)
Intermediate- risk population3 5 per 1000 fewer
events (16 fewer to
25 more)
781 (2) ⊕⊕©©
low5
LMWH may reduce
the
incidence of symp-
tomatic DVT when
compared with as-
pirin in mult iple
myeloma
24 per 1000 19 per 1000
(8 to 49)
1-year mortality
Follow-up: NA
NA6 Intermediate- risk population3 NA NA NA We do not know how
LMWH af fects 1-
year mortality when
compared with as-
pirin in mult iple
myelomaNA NA
Clinically relevant
bleeding
Follow-up: NA
NA6 Intermediate- risk population3 NA NA NA We do not know how
LMWH af fects clini-
cally relevant bleed-
ing when compared
with aspirin in mult i-
ple myelomaNA NA
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT : deep vein thrombosis; LM WH: low molecular weight heparin; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VTE: venous
thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the medium observed control group risk across the studies.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3
2
P
rim
a
r
y
p
ro
p
h
y
la
x
is
fo
r
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
in
a
m
b
u
la
to
r
y
c
a
n
c
e
r
p
a
tie
n
ts
re
c
e
iv
in
g
c
h
e
m
o
th
e
ra
p
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
3Intermediate-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to
the analyses (39 per 1000). Rates between 2% and 7% are considered intermediate risk (Khorana 2008).
4Downgraded (1 level) because of imprecision.
5Downgraded (2 levels) because of imprecision.
6No trials contributed to this outcome.
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Low molecular weight heparin compared with vitamin K antagonists for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: LMWH
Comparison: VKA
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
With VKA With LM WH
(any dosage)
Symptomatic VTE:
Follow-up: median
25 months
RR 0.33 (0.14 to 0.
83)
High- risk population3 55 per 1000 fewer
events (14 to 70
fewer)
439 (1) ⊕⊕⊕⊕
high4
LMWH reduces the
incidence of symp-
tomatic VTE when
compared to VKA in
mult iple myeloma
82 per 1000 27 per 1000
(11 to 68)
M ajor bleeding
Follow-up: median
25 months
RR not est imable5 High- risk population3 NA NA NA We do not know how
LMWH af fects major
bleeding when com-
pared to VKANA NA
Symptomatic PE
Follow-up: median
25 months
RR 0.11 (0.01 to 2.
06)
High- risk population3 16 per 1000 fewer
events (18 fewer to
19 more)
439 (1) ⊕⊕©©
low6
LMWH may re-
duce the incidence
of symptomatic PE
when compared to
VKA in mult iple
myeloma
18 per 1000 2 per 1000
(0 to 37)
Symptomatic DVT
Follow-up: median
25 months
RR 0.43 (0.17 to 1.
10)
High- risk population3 36 per 1000 fewer
events (53 fewer to
6 more)
439 (1) ⊕⊕⊕©
moderate7
LMWH probably re-
duces the incidence
of symptomatic DVT
when compared to3
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VKA in mult iple
myeloma
64 per 1000 27 per 1000
(11 to 70)
1-year mortality
Follow-up: NA
NA8 High- risk population3 NA NA NA We do not know how
LMWH af fects 1-
year mortality when
compared to VKANA NA
Clinically relevant
bleeding
Follow-up: NA
NA8 High- risk population3 NA NA NA We do not know how
LMWH af fects clini-
cally relevant bleed-
ing when compared
to VKANA NA
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; LM WH: low molecular weight heparin; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VKA: vitamin K
antagonists; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the observed control group risk in Palumbo 2011.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3High-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to the
analyses (82 per 1000). Rates f rom 7% and higher are considered high risk (Khorana 2008).
4Although there was some risk of attrit ion bias, imputat ion of the missing data in various ways showed that est imates would
not change in a clinically relevant manner (data not shown).
5Not est imable due to zero event count in both trial arms.
6Downgraded (2 levels) because of imprecision.
7Downgraded (1 level) because of imprecision.
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8No trials contributed to this outcome.
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Unfractionated heparin compared with no thromboprophylaxis for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: unf ract ionated heparin
Comparison: no thromboprophylaxis
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
Without UFH With UFH
Symptomatic VTE:
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
UFH af fects symp-
tomatic VTE.
NA NA
M ajor bleeding
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
UFH af fects major
bleeding.
NA NA
Symptomatic PE
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
UFH af fects symp-
tomatic PE.
NA NA
Symptomatic DVT
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
UFH af fects symp-
tomatic DVT.
NA NA
1-year mortality
Follow-up: 1 year
RR 0.86 (0.72 to 1.
03)
Population at unclear risk4 98 per 1000 fewer
events (195 fewer to
21 more)
277 (1) ⊕⊕©©
moderate5
UFH probably de-
creases the inci-
dence of 1-year mor-
tality in small cell
3
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lung cancer
698 per 1000 600 per 1000
(502 to 719)
Clinically relevant
bleeding
Follow-up: median
not reported,
maximum of 4.9
years of follow-up
RR 2.01 (0.18 to 21.
96)
Population at unclear risk4 7 per 1000 more
events (6 fewer to
151 more)
277 (1) ⊕©©©
low6
UFH may increase
the risk of clinically
relevant bleeding in
small cell lung can-
cer7 per 1000 14 per 1000
(1 to 158)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; UFH: unf ract ionated heparin; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the observed control group risk in Lebeau 1994.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3No trials contributed to this outcome.
4The risk prof ile refers to the median observed risk to experience symptomatic VTEs. As Lebeau 1994 did not report this
outcome, the risk prof ile remains unclear.
5Downgraded (1 level) because of imprecision.
6Downgraded (2 levels) because of imprecision.
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Vitamin K antagonists compared with placebo or no thromboprophylaxis for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: VKA
Comparison: placebo or no thromboprophylaxis
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
Without VKA With VKA
Symptomatic VTE:
Follow-up: mean 6
months
RR 0.15 (0.02 to 1.
2)
Intermediate- risk population3 37 per 1000 fewer
events (43 fewer to
9 more)
311 (1) ⊕⊕©©
low4
VKA may reduce
the incidence of
symptomatic VTE in
breast cancer44 per 1000 7 per 1000
(1 to 53)
M ajor bleeding
Follow-up: mean 6
months
RR 3.82 (0.97 to 15.
04)
Intermediate- risk population3 18 per 1000 more
events (0 fewer to 88
more)
994 (4) ⊕⊕©©
low5
VKA may increase
the incidence of
major bleeding in
breast cancer and
small cell lung can-
cer
6 per 1000 24 per 1000
(6 to 95)
Symptomatic PE
Follow-up: mean 6
months
RR 1.05 (0.07 to 16.
58)
Intermediate- risk population3 0 per 1000 fewer
events (6 fewer to
101 more)
311 (1) ⊕©©©
very low6
We have very lit -
t le conf idence in
the est imated ef fect
of VKA on symp-
tomatic PE in breast
cancer
6 per 1000 7 per 1000
(0 to 108)
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Symptomatic DVT
Follow-up: mean 6
months
RR 0.08 (0 to 1.42) Intermediate- risk population3 35 per 1000 fewer
events (38 fewer to
16 more)
311 (1) ⊕⊕©©
low4
VKA may reduce
the incidence of
symptomatic DVT in
breast cancer38 per 1000 3 per 1000
(0 to 54)
1-year mortality
Follow-up: NA
NA Intermediate- risk population3 NA NA NA We do not know how
VKA af fects 1-year
mortality.
NA NA
Clinically relevant
bleeding
Follow-up: NA
NA Intermediate- risk population3 NA NA NA We do not know how
VKA af fects clini-
cally relevant bleed-
ing.NA NA
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VKA: vitamin K antagonists; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the medium observed control group risk across the trials.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3Intermediate-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to
the analyses (44 per 1000). Rates between 2% and 7% are considered intermediate risk (Khorana 2008).
4Downgraded (2 levels) because of imprecision, the risk for publicat ion bias, as only 1 out of 4 trials reported on this outcome,
and potent ial at trit ion bias, see Characterist ics of included studies.
5Downgraded (2 levels) because of imprecision and potent ial at trit ion bias in 2 out of 4 trials.
6Downgraded (3 levels) because of imprecision (2 levels), the risk for publicat ion bias, as only 1 out of 4 trials reported on
this outcome, and potent ial at trit ion bias, see Characterist ics of included studies.
4
0
P
rim
a
r
y
p
ro
p
h
y
la
x
is
fo
r
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
in
a
m
b
u
la
to
r
y
c
a
n
c
e
r
p
a
tie
n
ts
re
c
e
iv
in
g
c
h
e
m
o
th
e
ra
p
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Vitamin K antagonists compared with aspirin for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: VKA
Comparison: aspirin
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
With aspirin With VKA
Symptomatic VTE:
Follow-up: median
2.1 years
RR 1.50 (0.74 to 3.
04)
Intermediate- risk population3 27 per 1000 more
events (14 fewer to
211 more)
440 (1) ⊕⊕⊕©
moderate4
VKA probably in-
creases the inci-
dence of symp-
tomatic VTE when
compared to aspirin
in mult iple myeloma
55 per 1000 82 per 1000
(40 to 166)
M ajor bleeding
Follow-up: median
2.1 years
RR 0.14 (0.01 to 2.
75)
Intermediate- risk population3 12 per 1000 fewer
events (14 fewer to
24 more)
440 (1) ⊕⊕©©
low5
VKA may reduce the
incidence of major
bleeding when com-
pared to aspirin in
mult iple myeloma
14 per 1000 2 per 1000
(0 to 38)
Symptomatic PE
Follow-up: median
2.1 years
RR 1.00 (0.25 to 3.
95)
Intermediate- risk population3 0 per 1000 fewer
events (14 fewer to
54 more)
440 (1) ⊕⊕⊕©
moderate4
VKA is probably as
ef fect ive as aspirin
in the prevent ion of
symptomatic PE in
mult iple myeloma
18 per 1000 18 per 1000
(5 to 72)
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Symptomatic DVT
Follow-up: median
2.1 years
RR 1.75 (0.75 to 4.
09)
Intermediate- risk population3 27 per 1000 more
events (9 fewer to
112 more)
440 (1) ⊕⊕⊕©
moderate4
VKA probably in-
creases the inci-
dence of symp-
tomatic DVT when
compared to aspirin
in mult iple myeloma
36 per 1000 64 per 1000
(27 to 149)
1-year mortality
Follow-up: NA
NA6 Intermediate- risk population3 NA NA NA We do not know how
VKA af fects 1-year
mortality when com-
pared to aspirin in
mult iple myelomaNA NA
Clinically relevant
bleeding
Follow-up: NA
NA6 Intermediate- risk population3 NA NA NA We do not know how
VKA af fects clini-
cally relevant bleed-
ing when compared
to aspirin in mult iple
myelomaNA NA
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VKA: vitamin K antagonists; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the observed control group risk in Palumbo 2011.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3Intermediate-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to
the analyses (55 per 1000). Rates between 2% and 7% are considered intermediate risk (Khorana 2008).
4Downgraded (1 level) because of imprecision. Although attrit ion bias may have occurred, it is unlikely to have changed the
results in a clinically relevant manner.
5Downgraded (2 levels) because of imprecision. Although attrit ion bias may have occurred, it is unlikely to have changed the
results in a clinically relevant manner.
6No trials contributed to this outcome.
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Antithrombin compared with placebo for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: ant ithrombin
Comparison: placebo
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
Without antithrom-
bin
With antithrombin
(any dosage)
Symptomatic VTE:
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
antithrom-
bin af fects symp-
tomatic VTE.NA NA
M ajor bleeding
Follow-up: median 4
months
RR 0.78 (0.03 to 18.
57)
Population at unclear risk4 4 per 1000 fewer
events (16 fewer to
293 more)
85 (1) ⊕©©©
very low5
We have very lit -
t le conf idence in the
est imated ef fect of
ant ithrombin on the
incidence of major
bleeding
17 per 1000 13 per 1000
(1 to 310)
Symptomatic PE
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
antithrom-
bin af fects symp-
tomatic PE.NA NA
Symptomatic DVT
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know how
antithrom-
bin af fects symp-
tomatic DVT.
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NA NA
1-year mortality
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know
how antithrombin
af fects 1-year mor-
tality.NA NA
Clinically relevant
bleeding
Follow-up: NA
NA3 Population at unclear risk4 NA NA NA We do not know
how antithrombin
af fects clinically rel-
evant bleedingNA NA
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the observed control group risk in Mitchell 2003.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3No trials contributed to this outcome.
4The risk prof ile refers to the median observed risk to experience symptomatic VTEs. As Mitchell 2003 did not report this
outcome, the risk prof ile remains unclear.
5Downgraded (3 levels) because of imprecision (2 levels) and attrit ion bias, see Characterist ics of included studies.
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Apixaban compared with placebo for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer pat ients receiving chemotherapy
Settings: outpat ient clinics
Intervention: apixaban
Comparison: placebo
Outcomes Relative effect (95%
CI)
Illustrative comparative risks* (95% CI) Difference2
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
What it means
Assumed risk1 Corresponding risk
Without apixaban With apixaban (any
dosage)
Symptomatic VTE:
Follow-up: median 3
months
RR 0.08 (0.01 to 0.
67)
High- risk population3 66 per 1000 fewer
events (24 to 71
fewer)
122 (1) ⊕⊕⊕©
moderate4
Apixaban probably
decreases the in-
cidence of symp-
tomatic VTE across
dif ferent cancer
types
71 per 1000 6 per 1000
(1 to 48)
M ajor bleeding
Follow-up: median 3
months
RR 0.62 (0.06 to 6.
63)
High- risk population3 6 per 1000 fewer
events (16 fewer to
96 more)
122 (1) ⊕⊕⊕©
low5
We are unsure
whether apixaban
increases the in-
cidence of major
bleeding across dif -
ferent cancer types17 per 1000 11 (1 to 113)
Symptomatic PE
Follow-up: median 3
months
RR 0.11 (0.00 to 2.
54)
High- risk population3 12 per 1000 fewer
events (14 fewer to
22 more)
122 (1) ⊕⊕©©
low5
We are unsure
whether apixaban
decreases the in-
cidence of symp-
tomatic
PE across dif ferent
cancer types
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14 per 1000 2 per 1000
(0 to 36)
Symptomatic DVT
Follow-up: median 3
months
RR 0.08 (0.01 to 0.
67)
High- risk population3 27 per 1000 fewer
events (10 to 29
fewer)
122 (1) ⊕⊕⊕©
moderate4
Apixaban probably
decreases the in-
cidence of symp-
tomatic DVT across
dif ferent cancer
types
29 per 1000 2 per 1000
(0 to 19)
1-year mortality
Follow-up: NA
NA6 High- risk population3 NA 0 (0) NA We do not know how
apixaban af fects all-
cause mortality.NA NA
Clinically relevant
bleeding
Follow-up: median 3
months
RR 1.87 (0.23 to 14.
91)
High- risk population3 30 per 1000 more
events (27 fewer to
480 more)
122 (1) ⊕⊕©©
low7
We are unsure how
much apixaban in-
creases the in-
cidence of clini-
cally relevant bleed-
ing across dif ferent
cancer types
34 per 1000 64 per 1000 (8 to
514)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT: deep vein thrombosis; NA: not applicable; PE: pulmonary embolism; RR: risk rat io; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The assumed risk is calculated f rom the medium observed control group risk in the study, see Summary of f indings 2.
2Dif ference calculated as the absolute risk dif f erence between the assumed risk and corresponding risk, expressed per 1000.
3High-risk populat ion refers to the median observed risk to experience symptomatic VTE in the trials contribut ing to the
analyses (71 per 1000). Rates f rom 7% and higher are considered high risk (Khorana 2008).
4Downgraded (1 level) because of attrit ion bias, see Characterist ics of included studies.
5Downgraded (2 levels) because of attrit ion bias, see Characterist ics of included studies, and imprecision.
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6No trials contributed to this outcome.
7Downgraded (2 levels) because of indirectness, as we combined the dif ferent dosages to increase the stat ist ical power we
introduced indirectness, and the risk of attrit ion bias, see Characterist ics of included studies.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
When used as primary thromboprophylaxis in ambulatory cancer
patients receiving chemotherapy, both the uLMWH semuloparin
and LMWH reduce the incidence of symptomatic VTE by about
half. Data on the risk of major bleeding were inconclusive; the
confidence intervals around the risk estimate for LMWH were
wide but close to statistical significance and the upper bound sug-
gested that heparin treatment could be associated with as much
as a doubling of the major bleeding risk. Both semuloparin and
LMWH reduced the incidence of symptomatic PE but had no sig-
nificant effects on one-year mortality. LMWHwas associated with
a significantly three-fold higher risk of clinically relevant bleeding
compared to no thromboprophylaxis. Some types of cancer, such
as pancreatic or lung cancer, obtained significant benefits from
LMWHprophylaxis in terms of symptomatic VTE reductionwith
no apparent increases in major bleeding.
One study inmyelomapatients receiving thalidomide- or lenalido-
mide-based regimens showed that LMWH was associated with
a 67% lower risk of symptomatic VTE compared with warfarin,
but this study was underpowered to show differences for major
bleeding. The lack of a control group receiving placebo or no
thromboprophylaxis prevents firm judgements about the efficacy
and safety of LMWH or warfarin in myeloma patients receiving
thalidomide- or lenalidomide-based regimens. The reduction of
symptomatic VTE with warfarin in non-myeloma patients was
not statistically significant and was potentially associated with an
increase in major bleeding. Apixaban was evaluated only in a dose-
finding study and antithrombin in a relatively small trial involving
paediatric patients. No RCT evaluated fondaparinux, dabigatran,
rivaroxaban, edoxaban, and mechanical interventions.
Quality of the evidence
The methodological quality of the individual studies ranged from
low to high (Figure 2). Analytical exploration of the effects of
design flaws was feasible for the comparison of LMWH versus
no thromboprophylaxis only. We found no evidence of design-
related biases. An inspection of the funnel plot and formal analysis
of asymmetry did not indicate asymmetry for the primary efficacy
outcome (Figure 4), suggesting the absence of publication bias or
other biases related to small study size (Figure 6).
Across comparisons, the quality of the evidence for symptomatic
VTE ranged from low to high. Semuloparin was evaluated in a
single study, although this study was relatively large and of high
methodological quality (Agnelli 2012). While it is very unlikely
that new evidence will change our confidence in the estimate of
the effects of LMWH or semuloparin compared to placebo/no
thromboprophylaxis or of LMWH compared to VKA, we are less
certain about the estimates of the other comparisons. The quality
of the evidence for major bleeding was at best low, indicating that
further research is very likely to have an important effect on our
confidence in the estimate of effect and is likely to change the esti-
mate (Guyatt 2008). The largest concern overall was imprecision
due to the small study size of the majority of the trials. We could
not judge the quality of the evidence for several outcomes across
comparisons due to incomplete reporting or the absence of events
in both trial arms.
See Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings
4; Summary of findings 5; Summary of findings 6; Summary
of findings 7; Summary of findings 8; Summary of findings 9;
Summary of findings 10.
Potential biases in the review process
Our systematic approach to searching, study selection, and data
extraction followed that described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). It is unlikely
that we have missed relevant trials, but frequent updates of this re-
view are warranted given that we identified several new trials since
the previous version of this review, which covered published trials
up to 2014 (Di Nisio 2012). We minimised data extraction errors
by using two independent review authors (MDN, MC). Judge-
ments on the grade of evidence were discussed with a third re-
view author (AR). We acknowledge that quality assessment leaves
room for different interpretations, especially where the quality of
reporting is poor. We applied strict rules regarding the risk of at-
trition bias, requiring that all randomised participants were anal-
ysed according to the intention-to-treat principle. We chose this
rather strict approach, as the incidence of symptomatic VTE varies
considerably between trials and may be rather low, so that even
a small proportion of participants not analysed may impact on
the study estimates if the fraction not analysed is associated with
the outcome. Other reviews have also applied this approach (Juni
2001; Rutjes 2009; Rutjes 2012). Following Cochrane guidance,
we included quotes and the arguments on which we based our
judgements, allowing the reader to reach different conclusions.
Our systematic approach and the consistency of the results (lack
of significant heterogeneity) increase confidence in the internal
validity of our findings.
One limitation in the interpretation of this review is the ’no differ-
ence’ findings. The lack of difference may be related to the small
number of RCTs and small number of studied participants or
events, or both, as well as the absence of a true effect. In this regard,
the non-significant association between semuloparin and LMWH
and major bleeding events could indeed be the result of the rel-
atively low number of events observed. For example, in the trial
by Agnelli 2012, which evaluated semuloparin, there were only
a total of 37 major bleeds; thus while the point estimate is 1.05
(seemingly reassuring), the upper value of the 95% confidence in-
terval is 2.00, which means that there could have been at most
48Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
a doubling of the major bleeding risk. With regard to LMWH,
there were 5 new trials with 2491 additional participants, which
resulted in a higher point estimate compared to the previous ver-
sion of this review (1.44 versus 1.30), but the confidence interval
remained wide.
Another limitation related to the small number of RCTs, poor re-
porting, or both, was our inability to conduct all subgroup analyses
for the primary efficacy outcome. We had planned to explore the
impact of the stage of cancer (metastatic versus non-metastatic)
and differences in the use of co-interventions in the trial groups
on the treatment effect. We performed subgroup analysis by type
of cancer for the lung and pancreatic cancers, albeit the data for
the pooled analysis were derived from only five and two studies,
respectively. The lack of reporting, as well as the heterogeneity of
the cancers treated, prevented us from assessing the importance
of background chemotherapy on the response to thromboprophy-
laxis. Finally, the lack of evidence precluded any inference on the
use of mechanical prophylaxis.
Agreements and disagreements with other
studies or reviews
The evidence on the use of thromboprophylaxis in ambulatory
cancer patients receiving chemotherapy was summarised by Rana
2009 and Lyman 2013, and more recently in the updated guide-
lines of the American Society of Clinical Oncology (Lyman 2015).
The current systematic review adds substantial evidence to the nar-
rative description provided by Rana 2009, as our systematic search
identified 19 additional studies (Agnelli 2012; Altinbas 2004;
Elit 2012; Kakkar 2004; Khorana 2015; Klerk 2005; Larocca
2012; Lebeau 1994; Lecumberri 2013; Levine 2012; Macbeth
2016; Maraveyas 2012; Mitchell 2003; Palumbo 2011; Pelzer
2015; Sideras 2006; Vadhan-Raj 2013; van Doormaal 2011;
Zwicker 2013). While most of the studies evaluated LMWH,
additional data were available for other anticoagulants such as
the uLMWH semuloparin, the direct orally administered factor
Xa inhibitor apixaban, unfractionated heparin (UFH), and an-
tithrombin. Eight of these studies evaluated the effects of prophy-
lactic doses of LMWH on survival as the primary outcome, while
reporting VTE events as secondary outcomes (Altinbas 2004;
Elit 2012; Kakkar 2004; Klerk 2005; Lecumberri 2013; Macbeth
2016; Sideras 2006; van Doormaal 2011). Although the focus was
not on VTE, and some cases may have been underdiagnosed, the
overall incidence of symptomatic VTE was comparable with the
other studies included in the review. In the recent update of Lyman
2013, nine RCTs and three systematic reviews, including the pre-
vious version of the current Cochrane review, were considered (Di
Nisio 2012). In addition to performing a more comprehensive
search of the literature, another advantage of the current review
over the other reviews is that we provided pooled estimates with
95%confidence intervals for both efficacy and safety outcomes, al-
lowing a better estimation of the risks and benefits of thrombopro-
phylaxis in this setting. Lastly, the use of a larger dataset allowed us
to stratify multiple outcomes by type of treatment. Despite these
differences, our conclusions are in line with those of Rana 2009,
Lyman 2013, and Lyman 2015 and do not support the widespread
use of primary thromboprophylaxis in ambulatory cancer patients.
Although both LMWH and semuloparin reduced the incidence
of symptomatic VTE, we cannot exclude a significant increase in
major bleeding. The confidence intervals around the risk of major
bleeding with LMWH did not exclude a risk of major bleeding
up to two-fold higher compared to no thromboprophylaxis. In a
previous meta-analysis of six studies comparing LMWH versus no
thromboprophylaxis, Kuderer 2009 obtained similar estimates of
effects for symptomatic VTE and major bleeding. This work was
published only as an abstract with limited data on the methods
and type of analysis performed, which hampers any comparison
with the current meta-analysis. Other narrative reviews recently
summarised the evidence on the use of thromboprophylaxis for
VTE in ambulatory cancer patients (Aikens 2013;Maxwell 2012).
These reviews lacked a systematic search of the literature and, as
for Rana 2009 and Lyman 2013, no meta-analysis or evaluation of
study quality items and assessment of risk of bias were performed.
The conclusions of our review differ somewhat from the most re-
cent guidelines of the AmericanCollege of Chest Physicians (Kahn
2012), which suggest primary thromboprophylaxis with LMWH
or UFH in ambulatory patients with solid tumours who have
additional risk factors for VTE (that is previous venous throm-
bosis, immobilisation, angiogenesis inhibitors, thalidomide and
lenalidomide) and a low risk of bleeding. Specific risk factors and
their combination in risk scores may help to identify subgroups
with a higher risk of VTE that may benefit substantially from
prophylaxis (Ay 2010; Khorana 2008; Khorana 2009; Khorana
2009a).
In an earlier post hoc analysis of the SAVE-ONCO study, rates
of VTE in the placebo arm were 5.4% in the high-risk popu-
lation and down to 1.3% in the lower-risk population (George
2011). The greatest reduction in VTE with thromboprophylaxis
was observed among moderate- to high-risk participants, with no
apparent increased incidence of clinically relevant bleeding across
the various levels of VTE risk. Similarly, in the post hoc analysis
of the Prophylaxis of Thromboembolism During Chemotherapy
(PROTECHT) study, rates of VTE were 11% in the high-risk
group down to 3% in the lower-risk group, and the stratification
of cancer patients reduced the NNTB from 50 in the full study
population to 15 in the higher-risk group (Verso 2012). Finally,
preliminary findings from the pilot study of Zwicker 2013 suggest
that microparticles may be a marker to stratify the risk and tailor
the use of thromboprophylaxis, although it may be hard to im-
plement these measurements for VTE risk stratification in routine
practice.
Randomised controlled trials on subgroups of cancer patients con-
sidered at higher risk of VTE are under way (e.g. NCT02048865;
NCT02555878), and this update included recent data from the
49Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
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Study of Dalteparin Prophylaxis in High-Risk Ambulatory Can-
cer Patients (PHACS), which randomised participants at increased
risk based on a Khorana score above 3 to LMWH prophylaxis or
no thromboprophylaxis (Khorana 2015). Although findings from
this study are encouraging, it should be noted that the study was
terminated prematurely due to poor accrual, and was therefore
underpowered.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When deciding whether to use primary antithrombotic prophy-
laxis in ambulatory cancer patients receiving chemotherapy, clin-
icians need to determine the patient’s baseline risk of venous
thromboembolism (VTE) and weigh the magnitude of benefit
with antithrombotic prophylaxis, especially on major clinical end-
points, against the risk of bleeding. Low molecular weight heparin
(LMWH) was associated with a 46% lower incidence of symp-
tomatic VTE and 41% reduced incidence of symptomatic pul-
monary embolism, respectively, although the absolute differences
were relatively small. Low molecular weight heparin did not in-
crease major bleeding when compared with no thromboprophy-
laxis, but the confidence intervals were wide and the upper limit
did not exclude a twice-as-high risk of bleeding with heparin. Co-
morbidities predisposing to bleeding, which often represent an
exclusion criterion in randomised controlled trials on anticoagu-
lants, might result in a greater number of major bleeding com-
plications and limit the use of thromboprophylaxis in ’real life’.
An additional concern may be the use of thromboprophylaxis in
some types of cancers, such as those in the brain, which are consid-
ered to be at risk for major bleeding, although preliminary data in
brain cancer seem reassuring and suggest a similar risk for LMWH
and placebo (Perry 2010). Furthermore, in a recent retrospective
analysis, LMWH at therapeutic doses did not increase the risk of
intracranial bleeding in patients with brain metastases (Donato
2015). Thus, despite the encouraging results of this review, rou-
tine prophylaxis in ambulatory cancer patients cannot be recom-
mended before safety issues are adequately addressed. Since this re-
view mainly included patients with locally advanced or metastatic
cancer, the results may not be generalisable to patients with earlier
stages of cancer. Of note is that marketing applications for the
ultra-low molecular weight heparin semuloparin have been with-
drawn worldwide, and it is therefore unlikely to ever be commer-
cially available (EMEA 2012).
Data on the use of thromboprophylaxis with anticoagulants other
than LMWH appear to be preliminary. Four studies compared the
vitamin K antagonist warfarin with placebo or no warfarin, but
only one reported on VTE. An almost four-fold increase in ma-
jor bleeding was observed with warfarin, which was close to, but
did not reach, statistical significance. While additional studies are
needed to clarify the efficacy and safety of warfarin, the bleeding
concerns and the complexity of vitaminK antagonist management
discourage the use of warfarin for primary prophylaxis in cancer
patients. The lack of an adequate control group in the studies of
myeloma patients hampers definitive recommendations for one
specific thromboprophylaxis over another. In addition, the trials
including myeloma patients focused on specific regimens (thalido-
mide- and lenalidomide-based combinations). These findings and
conclusions may not apply to all myeloma patients but only to
those who are receiving such therapies. As renal insufficiency often
complicates the course of multiple myeloma, caution should be
taken in the administration and dosing of drugs such as LMWH
or direct thrombin or factor Xa inhibitors with a predominant re-
nal clearance. Patient subgroups that might benefit from prophy-
laxis cannot currently be specified, however ongoing studies may
provide valuable information in this regard (e.g. NCT02048865;
NCT02555878).
Implications for research
Additional randomised studies are needed to clearly establish the
risk-to-benefit ratio of anticoagulants in ambulatory cancer pa-
tients receiving chemotherapy and to identify subgroups that may
benefit most from thromboprophylaxis, such as those with ad-
vanced lung or pancreatic cancer. The assessment of the net clinical
benefit, for example the reduction of the combined symptomatic
VTE and major bleeding, may prove to be more clinically relevant
than the independent evaluation of safety and efficacy.
Evidence-based thrombotic and bleeding risk assessment scores
may help in selecting subgroups that are at higher risk of VTE
and lower risk of bleeding complications. Several additional as-
pects related to thromboprophylaxis deserve further study, such as
the optimal doses and duration, patient preferences, and quality
of life. Future adequately sized studies should include the mea-
surement of compliance and persistence with parenteral and oral
treatment, and we would welcome explorations of compliance/
persistence as potential effect modifiers on clinical outcomes. Fi-
nally, cost analysis data on the use of anticoagulation in people
with cancer undergoing chemotherapy would be extremely valu-
able and supportive of a broader application of prophylaxis in the
future. Although data from the six ongoing trials will be invaluable
in addressing some of these issues (see Characteristics of ongoing
studies), we still need more adequately powered randomised con-
trolled trials evaluating the effects of the oral direct Xa inhibitors
and direct thrombin inhibitors (Weitz 2012). Two ongoing stud-
ies are evaluating apixaban, in NCT02048865, and rivaroxaban,
in NCT02555878, in high-risk subgroups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agnelli 2009
Methods PROTECHT study: multicentre, double-blind, placebo-controlled trial; modified in-
tention-to-treat analysis, including participants who received at least 1 dose of study
treatment
Participants Ambulatory patients older than 18 years of age who were receiving chemotherapy for
metastatic or locally advanced lung, gastrointestinal, pancreatic, breast, ovarian, or head
and neck cancer. Mean age (SD): 62.1 (10.3) years in the nadroparin group; 63.7 (9.2)
years in the placebo group; male sex, n (%): 372 (48.4) in nadroparin and 183 (48) in
placebo; metastatic disease, n (%): not reported; previous VTE: 12 (1.6%) in nadroparin
and 6 (1.6) in placebo. The median duration of follow-up was 111 and 113 days in the
nadroparin and placebo groups, respectively
Interventions Intervention: LMWH, nadroparin (3800 IU sc, once daily)
Control: placebo
Study treatment started on the same day as chemotherapy (the first cycle or a new course)
, and was given for the duration of chemotherapy or up to a maximum of 120 days (±
10 days)
Outcomes Primary outcomes: composite of symptomatic venous or arterial thromboembolic events
occurring during the study treatment plus 10 days; major bleeding that occurred between
randomisation and 48 hours after the last injection of the study drug
Secondary efficacy outcomes: incidental thromboembolic events incidentally diagnosed;
survival at the end of study treatment and at 12months; superficial venous thrombosis of
the lower limbs; response to chemotherapy; central venous catheter-related complications
of possible thrombotic origin
Secondary safety outcome: minor bleeding
Notes Antiplatelet agents, oral anticoagulants, fibrinolytic agents, unfractionated heparin, or
lowmolecular weight heparin other than nadroparin not allowed during the study period
Funding: Italfarmaco SpA, Milan, Italy
Disclosure of potential conflicts of interest: The scientific director of Italfarmaco was
involved as an author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation list was gen-
erated by an independent statistician who
used a standard permuted block of six with-
out stratification. The list was generated
with SAS version 8.2.”
Comment: adequate method of sequence
generation
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Agnelli 2009 (Continued)
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was avail-
able online to the investigators using the
Hypernet web-based system. At the time
the investigator accessed the web-based sys-
tem with personal codes (user ID and pass-
word) and requested the treatment alloca-
tion for a newpatientwho fulfilled the eligi-
bility criteria, the system assigned the next
free number in accordance with the ran-
domisation sequence”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Patients and investigators did not
know whether study drug or placebo was
being given, since pre-filled syringes were
used which were identical in appearance.
Treatment assignments were masked from
all study personnel and participants for the
duration of the study.”
“All study outcomes were assessed by a cen-
tral independent adjudication committee
whose members were unaware of patients’
study-group allocation”
Comment: double-blinded RCT and ade-
quate methods of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “All randomised patients who re-
ceived at least one dose
of the study treatment were included in the
efficacy and
safety analyses”
Comment: 769 out of 779 (98.7%) par-
ticipants randomised were analysed in the
LMWH group, 381 out of 387 (98.4%)
randomised were analysed in the placebo
group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
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Agnelli 2012
Methods SAVE-ONCO study: multicentre, double-blinded RCT, intention-to-treat for effective-
ness and modified intention-to-treat analysis for safety outcomes, including participants
who received at least 1 study dose
Participants Patients with metastatic or locally advanced solid cancer of the lung, pancreas, stomach,
colon or rectum, bladder, or ovary who were beginning a course of chemotherapy. Mean
age: 59.8 years in the semuloparin group and 59.4 years in the placebo group. Male,
n (%): 974 (60.6) in semuloparin and 956 (59.6) in placebo; metastatic disease: not
reported; previous VTE: 2% in semuloparin and 2.3% in placebo. Mean duration of
follow-up: not reported
Interventions Intervention: uLMWH semuloparin (20 mg sc, once daily)
Control: placebo
The first dose of the study drug was administered on the first day of a course of chemo-
therapy (first regimen or a new regimen), continuing for the duration of chemotherapy
(intended to be a minimum of 3 months). Median treatment duration was 3.5 months
Outcomes Primary efficacy outcome: composite of any symptomatic DVT, any non-fatal PE, and
death related to VTE
Primary safety outcome: clinically relevant bleeding (major and non-major)
Secondary efficacy outcome: 1-year overall survival or at the study end date
Notes Funding, quote: “Supported by Sanofi”. “The study was designed by the steering com-
mittee members and sponsored by Sanofi. Data were collected through a clinical research
organization and analyzed by Sanofi. No Sanofi employees were members of the steering
committee or the data and safety monitoring board”
Disclosure of potential conflicts of interest: In the section “The Work Under Consid-
eration for Publication”, some of the authors declared they were employed by Sanofi or
had received consulting fee or honorarium and support for travel to meetings by Sanofi-
Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed
centrally by means of an interactive voice-
response system.”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed
centrally by means of an interactive voice-
response system.”
Comment: adequate method of allocation
concealment
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Agnelli 2012 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Efficacy and bleeding outcomes
were assessed by a central independent
adjudication committee, whose members
were unaware of the study treatment”
Comment: double-blinded RCT and
blinding of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All patients who underwent ran-
domization were included in the pri-
mary efficacy population (intention-to-
treat population), and those who under-
went randomization and received at least
one dose of the study treatment were in-
cluded in the safety population”
Comment: For safety, 1589 out of 1608
participants (98.8%) randomised are anal-
ysed in the uLMWH group, 1583 out of
1604 participants (98.7%) randomised are
analysed in the placebo group
Selective reporting (reporting bias) Low risk All outcomes reported in the protocol and
in the methods section of the full report
were addressed in the results or discussion
section, except for 1 outcome mentioned
in the protocol only: “Secondary efficacy
variables include the initiation of curative
treatment by the investigator after VTE”.
We did not consider this outcome to be
relevant for the current review
Altinbas 2004
Methods RCT; intention-to-treat analysis for survival outcomes
Participants Patients between ages 18 and 75 years with histologically confirmed small cell lung
carcinoma with an ECOG performance status of less than 3 and normal haematological,
renal, and hepatic function tests. Median age: 58 years (range 34 to 75); gender, n: 33
males and 9 females in dalteparin, 35 males and 7 females in control; metastatic disease,
n: 19 in dalteparin and 17 in control; previous VTE: 0/84. Median duration of follow-
up: 10 months (range 2 to 33 months)
Interventions Intervention: LMWH, dalteparin (5000 IU sc, once daily)
Control: no dalteparin
Dalteparin was stopped with disease progression or at the end of the 18 weeks of che-
motherapy
Median duration of treatment was 18 weeks.
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Altinbas 2004 (Continued)
Outcomes Primary outcome: overall survival
Secondary outcomes: progression-free survival, side effects
Notes Funding: not reported
Disclosure of potential conflicts of interest: not disclosed, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were randomized to re-
ceive either CT or CT plus LMWH“
Comment: method of random sequence
generation not reported
Allocation concealment (selection bias) Unclear risk Quote: ”Patients were randomized to re-
ceive either CT or CT plus LMWH“
Comment: method of allocation conceal-
ment not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: The trial is reported as a ”Che-
motherapy-only“ versus Chemotherapy +
LMWH” trial, without mentioning the use
of placeboLMWH,or any attempt to blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: For effectiveness is not re-
ported. For safety, survival is analysed ac-
cording to the intention-to-treat principle
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion section
Chahinian 1989
Methods Multicentre, 3-arm RCT, type of analyses not reported
Participants Patients with extensive carcinoma of the lung. Patients aged 60 years or older: 55%
warfarin and 60% control group; males: 68% and 67%, respectively. Metastatic or
extensive disease: 100%; previous VTE: not reported
Interventions Intervention: warfarin to maintain a prothrombin 1.5 to twice the control values
Control: no warfarin
Warfarin was continued throughout the course of chemotherapy, and it was withheld
in participants with brain metastases during cranial irradiation and whenever platelet
counts fell below 75,000/µL
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Chahinian 1989 (Continued)
Outcomes Main outcomes: overall survival, failure-free survival, and cancer response (complete
response, partial response, and objective response rate) to therapy
Secondary outcomes: toxicity
Notes Funding: grants from the National Cancer Institute, Department of Health and Human
Services, and the T.J. Martell Foundation for Leukemia and Cancer Research
Disclosure of potential conflicts of interest: not disclosed, no COI forms available
2 out of 3 available trial armswere considered in this review, as the chemotherapy provided
was the same in both arms. The excluded trial arm provided a different chemotherapy
regimen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “allocation was determined by a
Latin square arrangement balancing the se-
quence within and across institutions”
Comment: adequate method of sequence
generation; stratified randomisation, use of
Latin square design
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Comment: blinding not reported, use of
placebo warfarin not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 34 out of 328 participants
(10%) enrolled in the study were not con-
sidered for the analysis. Exclusions per trial
arm were not reported
Selective reporting (reporting bias) Unclear risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion section. Toxicity was ad-
dressed in the results, but not explicitly re-
ported as an outcome in the methods sec-
tion
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Elit 2012
Methods Multicentre, open-label, phase II randomised trial with 3 active treatment arms
Participants Women with newly diagnosed epithelial ovarian cancer stage IIB to IV. Age, median
(min-max): 61 years (34, 74); female: 100%; metastatic disease: not reported; previous
VTE, n (%): 4 (5)
Interventions Intervention 1: standard adjuvant chemotherapy (taxane and platinum-based) and dal-
teparin 50 IU/kg subcutaneously once daily during the first 3 of 6 cycles of 3-weekly CT
Intervention 2: standard adjuvant chemotherapy (taxane and platinum-based) and dal-
teparin 100 IU/kg subcutaneously once daily during the first 3 of 6 cycles of 3-weekly
CT
Intervention 3: standard adjuvant chemotherapy (taxane and platinum-based) and dal-
teparin 150 IU/kg subcutaneously once daily during the first 3 of 6 cycles of 3-weekly
CT
Studymedicationwas startedwithin 7days prior to the first 21-day cycle of chemotherapy
and continued until day 21 of cycle 3
Outcomes Primary outcome: tumour response defined by≥ 50% reduction in serum CA125 from
baseline sustained for at least 28 days
Secondary outcomes: major bleeding up to 24 hours after the last dose of dalteparin; any
bleeding up to 24 hours after the last dose of dalteparin; symptomatic VTE up to 7 days
after the last dose of dalteparin; death up to the last day of follow-up; and compliance
with dalteparin administration
Participants were followed until the end of CT.
Notes Funding, quote: “The Steering Committee wishes to acknowledge the financial support
from both the Juravinski Cancer Centre Foundation and Pfizer Canada Inc”
Disclosure of potential conflicts of interest, quote: “There are no financial disclosures
from any of the authors related to this work except for Dr. Lee who has provided
educational lectures and received financial reimbursement from Pfizer Canada Inc.”
Quote: “The study was terminated early due to poor recruitment.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Concealed randomization was
performed centrally ... using a computer-
generated, permuted-block randomization
schedule.”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Concealed randomization was
performed centrally ... using a computer-
generated, permuted-block randomization
schedule.”
Comment: adequate method of allocation
concealment
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Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “Study outcomes were adjudicated
by members of a Central Adjudication
Committee masked to treatment assign-
ment.”
Comment: open-label study with blinded
adjudication of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The primary analysis included all
patients as randomized”
Comment: All participants who were ran-
domised were included in the analysis
Selective reporting (reporting bias) Low risk Comment: All outcomes indicated in the
methods are presented in the results
Haas 2012
Methods TOPIC-1 and TOPIC-2 studies: multicentre RCTs, intention-to-treat analysis for ef-
fectiveness and modified intention-to-treat analysis for safety outcomes
Participants Patients with metastatic breast cancer (n = 353) or non-small cell lung carcinoma (n =
547) receiving first- or second-line chemotherapy. In the TOPIC-1 study (breast cancer
patients), the mean age (SD) was 54.6 (10.3) years in the certoparin group and 56.6
(11.0) years in the placebo group. In the TOPIC-2 study (lung cancer patients), the
mean age (SD) was 60.8 (9.5) years in the certoparin group and 60.3 (10.0) years in the
placebo group. Males, n (%): TOPIC-1: none, TOPIC-2: 227 (83.2) in both certoparin
and placebo; metastatic disease: not reported; previous VTE: 0/900
Interventions Intervention: LMWH, certoparin (3000 IU sc, once daily)
Control: placebo
Study treatment was given for 6 months.
Outcomes Primary outcomes: symptomatic or incidental VTE, major bleeding
Secondary outcomes: symptomatic VTE, overall thrombosis rate (to include arterial
thrombotic events, superficial venous thrombosis, and central-line thrombosis), mi-
nor bleeding, thrombocytopenia, heparin-induced thrombocytopenia, osteoporotic frac-
tures, survival
Post hoc: mortality, symptomatic or incidental VTE according to tumour stage
Notes Funding: grant from Novartis Pharma, Nuremberg, Germany. Quote: “The TOPIC
studies were supported by an unrestricted grant fromNovartis PharmaGmbH,Germany.
”
Disclosure of potential conflicts of interest, quote: “The author(s) declared no potential
conflicts of interest with respect to the research, authorship, and/or publication of this
article.”
The study on breast cancer was prematurely halted after an interim analysis
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a computer-generated ran-
domisation list” and “Randomization was
block-stratified according to treatment
with hormone-based chemotherapy”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “Randomization numbers were al-
located sequentially as patients were en-
rolled at each center.”
Comment: Concealment of allocation was
poorly reported. It was not reported if
sealed, opaque, and consecutively num-
bered envelopes, coded syringes, or other
methods were used. In addition, it re-
mains unclear what is meant by randomisa-
tion number in “Patients were allocated to
the lowest available randomisation number
available for each study center.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Efficacy outcomes were validated
by a blinded, independent Central Throm-
bosis Evaluation Team; safety end points
were validated by a Data Safety Monitor-
ing Committee consisting of 2 clinicians
(blinded to treatment) and an independent
statistician with access to the treatment as-
signments.” and “Only the external statisti-
cian from the Safety Committee had access
to the randomization codes.”
Comment: double-blinded, placebo-con-
trolled RCT with blinding of participants,
physicians, and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For effectiveness, 442 out of
447 (98.9%) in the LMWHgroup and 441
out of 453 (97.4%) in the placebo group
were analysed. For safety, 447 out of 447
(100%) in the LMWH group and 451 out
of 453 (99.6%) in the placebo group were
analysed
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
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sults or discussion section. However, the
outcome osteoporotic fracture was incom-
pletely reported; it remained unclear in
which of the TOPIC-2 trial arms the sin-
gle event occurred. Post hoc analyses were
reported transparently
Kakkar 2004
Methods FAMOUS study: double-blind, placebo-controlled, multicentre RCT; modified inten-
tion-to-treat analysis for both effectiveness and safety analyses, including participants
with at least 1 study dose and 1 follow-up visit
Participants Patients of 18 and 80 years with histologically confirmed advanced stage III or IV (locally
advanced or metastatic) malignant disease of the breast, lung, gastrointestinal tract,
pancreas, liver, genitourinary tract, ovary, or uterus. Age: 62 years in the dalteparin group
and 60.9 years in the placebo group; female, n (%): 113 (59.5) in dalteparin and 100
(54.3) in placebo; metastatic disease, n: 161 in both dalteparin and placebo; previous
VTE: 0/385. Median duration of follow-up: 10 months in the dalteparin group and 9
months in the placebo group
Interventions Intervention: LMWH, dalteparin (5000 IU sc, once daily)
Control: placebo (0.9% normal saline)
Study treatment given for 1 year or until the participant died, whichever occurred sooner
Outcomes Primary outcomes: mortality after 1 year of therapy
Secondary outcomes: symptomatic, objectively confirmed VTE disease and bleeding
complications
Notes Funding: Pharmacia Corp, New York, NY
Disclosure of potential conflicts of interest: The lead author declared having acted as a
consultant for Pfizer. Quote: “The following authors or their immediate family members
have indicated a financial interest. No conflict exists for drugs or devices used in a study if
they are not being evaluated as part of the investigation. Acted as a consultant within the
last 2 years: Ajay K. Kakkar, Pfizer. Received more than $2,000 a year from a company
for either of the last 2 years: Ajay K. Kakkar, Pfizer”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed
centrally by computer-generated code”
Comment: adequate method of sequence
generation
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Allocation concealment (selection bias) Low risk Quote: “Randomization was performed
centrally by computer-generated code”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “placebo (0.9% normal saline),
each supplied in 0.2-mL prefilled
syringes”
Comment: trial reported as double-blind,
with active substance or placebo provided
in prefilled syringes. It is not reported
whether syringes were identical in appear-
ance
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Both for effectiveness and sa-
fety, 190 out of 196 (96.9%) were anal-
ysed in the LMWH group and 184 out of
189 (97.4%) were analysed in the placebo
group
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion section
Khorana 2015
Methods PHACS trial: a multicentre RCT
Participants Cancer patients at high risk for VTE (Khorana score ≥ 3) and initiating a new systemic
chemotherapy regimen. Mean age (SD): dalteparin 60 (10) and observation 58 (12);
gender, female/male: 21/29 dalteparin and 24/24 observation; metastatic disease: not
reported; previous history of VTE, n (%): dalteparin 4 (8) and observation 2 (4)
Interventions Intervention: LMWH, dalteparin 5000 IU daily subcutaneously for 12 weeks
Control: no dalteparin
Outcomes Primary outcome: any VTE over 12 weeks
Participants in both arms were screened with lower extremity ultrasounds every 4 weeks
of study
Primary safety endpoint was clinically relevant bleeding events over 13 weeks
Notes NCT00876915
Funding: not reported
Disclosure of potential conflicts of interest: All authors report conflicts of interest
The study was terminated due to poor accrual.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized to either dalteparin 5000 units
daily subcutaneously or no prophylactic anticoagu-
lation”
Comment: method of sequence generation not re-
ported
Allocation concealment (selection bias) Unclear risk Quote: “randomized to either dalteparin 5000 units
daily subcutaneously or no prophylactic anticoagu-
lation”
Comment: method of allocation concealment not
reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Comment: It is not reported whether participants,
personnel, and outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of 117 enrolled patients, 19 were not ran-
domized due to the presence of VTE on initial
screening (N =10, 8.5%) or for other reasons (N =
9).”
Comment: All randomised participants were in-
cluded in the analysis
Selective reporting (reporting bias) Low risk Comment: All outcomes indicated in the methods
of the abstract are reported in the results
Klerk 2005
Methods MALT study: multicentre, double-blinded, randomised, placebo-controlled study with
intention-to-treat analyses for both effectiveness and safety, including participants who
received at least 1 study dose
Participants Patients with metastasised or locally advanced solid tumours. Median age (range): 63
years (36 to 86) in the nadroparin group and 64 years (28 to 83) in the placebo group;
male, n (%): 77 (52) in nadroparin and 81 (53) in placebo; metastatic disease, n (%):
137 (93) in nadroparin and 139 (90) in placebo; previous VTE: 0/302. Mean duration
of follow-up: 12 months
Interventions Intervention: LMWH, nadroparin
Control: placebo
Prelled syringes containing a fixed volume of nadroparin (9500 anti-factor Xa U/mL)
or placebo were provided according to participant’s weight: 0.4 mL for those weighing
less than 50 kg, 0.6 mL for those weighing between 50 kg and 70 kg, and 0.8 mL for
those weighing more than 70 kg. Study treatment was to be administered sc twice daily
during the initial 14 days of treatment and once daily thereafter for another 4 weeks
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Outcomes Primary efficacy outcome: death from any cause
Primary safety outcome: major bleeding
Secondary safety outcome: clinically relevant non-major bleeding
Notes Funding: The study treatment was provided by Sano-Synthelabo (Paris, France). The
authors state that “protocol design, data collection, and analysis were solely the respon-
sibility of the authors”
Disclosure of potential conflicts of interest: The senior author and statistician declared
consultancy activities for various pharmaceutical companies, including Sanofi-Synthe-
labo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Sequentially numbered boxes of
syringes with nadroparin or placebo were
prepared using a central computer-gener-
ated randomization schedule, stratified for
body weight with blocks of four”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Sequentially numbered boxes of
syringes with nadroparin or placebo were
prepared using a central computer-gener-
ated randomization schedule, stratified for
body weight with blocks of four”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Prefilled syringes containing a
fixed volume of nadroparin (9,500 antifac-
tor Xa U/mL) or placebo were provided ac-
cording to patient’s weight”
Comment: trial reported as double-blind,
with active substance or placebo provided
in prefilled syringes. It is not reported
whether syringes were identical in appear-
ance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All enrolled participants were
included in the analysis
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion section. The authors re-
ported reasons for the discontinuation of
the study drug in the results section only,
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but this was for descriptive purposes, so un-
likely to introduce bias
Larocca 2012
Methods Prospective, multicentre, open-label, randomised substudy of a phase III trial with mod-
ified intention-to-treat analyses of both effectiveness and safety outcomes, including par-
ticipants who received at least 1 study dose
Participants Patients with newly diagnosed multiple myeloma treated with lenalidomide and low-
dose dexamethasone induction and melphalan-prednisone-lenalidomide consolidation.
Median age: 57 years in the aspirin group, 58 years in the enoxaparin group; male, n (%)
: 87 (49) in aspirin and 99 (60) in LMWH; metastatic disease: not reported; previous
VTE: 0/342
Interventions Intervention 1: LMWH, enoxaparin (40 mg/day sc)
Intervention 2: aspirin (100 mg/day)
Prophylaxis was provided during the 4 (28-day) cycles of lenalidomide and low-dose
dexamethasone and the 6 (28-day) cycles of melphalan-prednisone-lenalidomide con-
solidation
Median treatment duration was 3.6 months for aspirin and 3.5 months for LMWH
Outcomes Primary endpoint: composite of symptomatic DVT, PE, arterial thrombosis, any acute
cardiovascular event, or sudden otherwise-unexplained death in the first 6 months after
randomisation
Secondary outcomes: major and minor bleeding, any complications related to thrombo-
prophylaxis
Notes Funding: The main study (RV-MM-PI209) was supported by Fondazione Neoplasie
Sangue Onlus, and Celgene supplied free lenalidomide. The authors declared that Cel-
gene had no role in the study design, data analysis, data interpretation, or writing of the
report
Disclosure of potential conflicts of interest: Several authors declared having received
honoraria or consultancy fees fromvarious pharmaceutical companies, includingCelgene
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “simple randomization sequence
run by a central computer, which gener-
ated an automated assignment procedure
that was concealed from the investigators
in each study center”
Comment: adequate method of sequence
generation
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Allocation concealment (selection bias) Low risk Quote: “simple randomization sequence
run by a central computer, which gener-
ated an automated assignment procedure
that was concealed from the investigators
in each study center”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “Open-label” study
Comment: open study with no blinding of
participants, physicians, and outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All randomised participants
were included in the analysis
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion section
Lebeau 1994
Methods Multicentre, open-label, randomised substudy, with intention-to-treat analyses
Participants Patients with limited and extensive small cell lung cancer who had not been previously
treated with chemotherapy or radiotherapy. Male, n (%): 120 (87) in heparin and 132
(95) in control; extensive disease: 74 (54) in heparin and 82 (59) in control; previous
VTE: not reported
Interventions Intervention: chemotherapy with sc UFH. The dose of UFH was initially adapted to
weight (500 IU/kg/day) then adjusted by clotting times. UFHwas administered in 2 or 3
daily injections for 5 weeks and stopped 1 week after the second course of chemotherapy
Control: chemotherapy without UFH
Outcomes Primary outcome: overall survival, response to chemotherapy
Secondary outcomes: bleeding, UFH-related thrombocytopenia
Notes Funding: none reported
Disclosure of potential conflicts of interest: not disclosed, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized through a centralized
blind telephone assignment procedure”
Comment: method of sequence generation
not clearly reported
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Allocation concealment (selection bias) Low risk Quote: “randomized through a centralized
blind telephone assignment procedure”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “No bIinding procedure for pa-
tients and physicians was used”
Comment: open label study with no blind-
ing of participants or physicians. Not re-
ported if there was blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “No patient was lost to follow up”
Comment: All participants enrolled in the
randomised substudy were analysed
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults section
Lecumberri 2013
Methods Adjuvant Bemiparin in Small Cell Lung Cancer (ABEL) study: a multicentre, investiga-
tor-initiated, open-label, randomised study
Participants Patients with newly diagnosed, limited-stage small cell lung cancer. Mean age 62.7 ± 8.
9 years; 33 males and 5 females; previous VTE: none; metastatic disease: none
Interventions Intervention: standard chemoradiotherapy plus bemiparin 3500 IUdaily for amaximum
of 26 weeks
Bemiparin was started on the first day of the first cycle of chemotherapy and stopped at
disease progression or at the end of the 26 weeks of treatment
Control: standard first-line platinum-based chemotherapy and radiotherapy
Outcomes Primary efficacy outcome: progression-free survival
Primary safety outcome: major bleeding
Secondary outcomes were overall survival, tumour response rate to chemoradiotherapy,
incidence of objectively confirmed symptomatic VTE, minor bleeding, thrombocytope-
nia, death from any cause, and incidence of any other adverse event
Notes Funding, quote: “Bemiparin 3,500 IU syringes were provided without charge by Lab-
oratorios Farmacéuticos ROVI. S.A. The company also gave economic support for the
expenses of the CRO, but was not directly involved in the design of the study, collection
or analysis of the data or in the preparation of the manuscript.”
Quote: “The study was terminated early due to slow recruitment”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed
through an automatic central randomiza-
tion system”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed
through an automatic central randomiza-
tion system”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “there was no central adjudication
committee.”
Comment: open study with unblinded ad-
judication of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 1 of 39 (2.56%) included par-
ticipants was excluded from the analysis
Selective reporting (reporting bias) Low risk Comment: All outcomes indicated in the
methods are reported in the results
Levine 1994
Methods Multicentre, double-blind, randomised, placebo-controlled trial; intention-to-treat anal-
ysis
Participants Patients with metastatic stage IV breast carcinoma who had been receiving first- or
second-line chemotherapy for 4 weeks or less. Mean age: 57 years in the warfarin group
and 56 years in the placebo group; metastatic disease: not reported; previous VTE: none
in warfarin and 2/159 in placebo. Mean duration of follow-up: 199 days (SD 126) for
warfarin and 188 days (SD 137) for placebo
Interventions Intervention: warfarin (1 mg daily for 6 weeks and then adjusted to maintain the INR
between 1.3 to 1.9)
Control: placebo
Study treatment began either at the start of chemotherapy or within the next 4 weeks
and continued until 1 week after termination of chemotherapy
Median treatment duration: 181 days (SD 123) for warfarin and 166 (SD 139) for
placebo
Outcomes Primary outcomes: VTE and arterial thrombosis; major and minor bleeding
Secondary outcome: survival
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Notes Funding: study supported by a grant-in-aid from theNationalCancer Institute ofCanada
Disclosure of potential conflicts of interest: none disclosed, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “according to a computer-gener-
ated random arrangement.”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Unclear risk Comment: method of allocation conceal-
ment not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “neither patients nor doctors were
aware of treatment allocation” and “All
outcome events were reviewed by a cen-
tral adjudicating committee, unaware of
treatment allocation” and “placebo patients
took an identical inert tablet”
Comment: adequate blinding of partici-
pants, physicians, and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For effectiveness and safety, 152
out of 154 (98.7%) in the warfarin and 159
out of 161 (98.8%) in the placebo group
were analysed
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults
Levine 2012
Methods Randomised, double-blind, phase II trial; intention-to-treat analyses not reported
Participants Patients receiving either first- or second-line chemotherapy for advanced or metastatic
lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer; cancer of unknown
origin; myeloma; or selected lymphomas. Median age (years, range): 57 (41 to 67) in
apixaban 5 mg, 60 (39 to 76) in 10 mg, 64 (25 to 86) in 20 mg, and 59 (20 to 82) in the
placebo group; male, n (%): 15 (46.9), 13 (43.3), 20 (60.6), and 15 (50), respectively;
advanced or metastatic: 100%; previous VTE: 0/125
Interventions Intervention: factor Xa inhibitor, apixaban (5 mg, 10 mg, or 20 mg once daily oral)
Control: placebo
Study treatment was given for 12 weeks beginning within 4 weeks of starting chemo-
therapy
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Median treatment duration for apixaban 5 mg, 10 mg, and 20 mg and placebo: 79.2
(29 to 90) days, 76.0 (16 to 90) days, 73.6 (14 to 92) days, and 69.6 (7 to 91) days,
respectively
Outcomes Primary outcome: major bleeding or clinically relevant non-major bleeding
Secondary outcomes: VTE, grade III or higher adverse events related to study drug
Notes Trials closed prematurely due to slow accrual rate.
Funding, quote: “The study was sponsored by Bristol-Myers Squibb and Pfizer Inc.”
Disclosure of potential conflicts of interest: No other COI reported, no COI forms
available, but 2 of the authors were employees of the sponsor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed
centrally by contacting a computerised tele-
phone voice response system provided by
Bristol Myers Squibb”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed
centrally by contacting a computerised tele-
phone voice response system provided by
BristolMyers Squibb” and “BMSgenerated
and kept the randomization schedules.”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Double-blind” study, “treatment
groups or all placebo tablets for the placebo
treatment group such that the study sup-
plies for subjects in all treatment groups
were identical in appearance”, and “All
bleeding and VTE events were adjudicated
by a committee unaware of treatment allo-
cation.”
Comment: participants, physicians, and
outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: for effectiveness and safety, 32
out of 32 (100%) analysed in the 5 mg
group; 29out of 30 (96.7%) analysed in the
10 mg group; 32 out of 33 (97%) analysed
in the 20 mg group; and 29 out of 30 (96.
7%) analysed in the placebo group.None of
these excluded participants received study
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treatment, and we cannot rule out that
their exclusion was associated with the out-
come. In addition to these 3 excluded par-
ticipants, it also remains unclear why the 5
participants (4%) enrolled after the proto-
col amendment were not considered in the
analyses
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults section
Macbeth 2016
Methods The FRAGMATIC trial: an open-label, multicentre, parallel-group, superiority, ran-
domised phase III trial. Median follow-up of 23.1 months (IQR 3.6 to 31.2 months)
Participants Patients with histopathologic or cytologic diagnosis of primary bronchial carcinoma of
any stage and histology (small cell or non-small cell) within 6 weeks. Median age, years
(IQR): LMWH 65 (59 to 71) and control 64 (58 to 71); female, n (%): LMWH 440
(40.0) and control 444 (40.4); metastatic disease, n(%): LMWH 670 (60.9) and control
666 (60.5); previous VTE: not reported
Interventions Intervention: standard anticancer treatment (including active supportive or palliative
care) plus dalteparin (5000 IU subcutaneously once daily) for a maximum of 24 weeks
Dalteparin was started as soon as possible and before first definitive anticancer treatment
Control: standard anticancer treatment (including active supportive or palliative
care)
Use of prophylactic anticoagulant outside of trial (short-term use, e.g. inpatient
thromboprophylaxis, and therapeutic anticoagulation were allowed if clinically indicated
according to local guidelines), n (%):
LMWH 106 (9.7)
Control 88 (8.0)
Outcomes Primary outcome: overall survival
Secondary outcomes: VTE-free survival, bleeding (major and clinically relevant non-
major), metastasis-free survival, toxic effects, quality of life, dyspnoea, cost-effectiveness,
and cost utility
Compliance with dalteparin was assessed by counting empty syringes at follow-up visits
and from the local pharmacy logs
Notes Funding, quote: “Supported by Cancer Research UK Grant No. CR UK/06/007, an
educational grant from Pfizer, and the National Institute for Health Research Cancer
Network; sponsored by Velindre National Health Service Trust, Cardiff; and coordinated
by the Cancer Research UK core-fundedWales Cancer Trials Unit at Cardiff University”
Disclosure of potential conflicts of interest: Some of the authors report conflict of interest
Quote: “The trial did not reach its intended number of events for the primary analysis”
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients were randomly
assigned by theWales Cancer Trials Unit in
a 1:1 ratio to receive either LMWH or no
LMWH, by use of a computer algorithm
using the method of minimization and a
random element”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Allocation concealment was by re-
search nurses (who recruited patients) tele-
phoning the Wales Cancer Trials Unit,
where randomization and treatment alloca-
tion was done by a trial/datamanager using
a computerized system.”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “The study had an open-label de-
sign”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All analyses were performed using
intention to treat.”
Comment: For the analysis of the primary
outcomes and most of the secondary out-
comes, all randomised participants were
apparently included in the analysis. For the
evaluation of compliance with LMWH,
977 of 1101 participants were assessed
Selective reporting (reporting bias) Low risk Comment: All outcomes indicated in the
methods are reported in the results of the
main or related papers
Maraveyas 2012
Methods FRAGEM study: phase IIb RCT; intention-to-treat analyses not reported
Participants Patients with non-resectable, recurrent, or metastatic pancreatic adenocarcinoma. Me-
dian age: 63 years (range 40 to 82); males: 59%; patients with metastatic disease: 54%;
previous VTE: 0/123. Median follow-up time: 19.3 months
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Interventions Intervention: LMWH, dalteparin (200 IU/kg once daily, sc for 4 weeks followed by a
stepdown to 150 IU/kg for a further 8 weeks) and gemcitabine
Continuing dalteparin prophylaxis beyond 12 weeks was not recommended, but was
left to the discretion of the investigator
Control: gemcitabine with no dalteparin
Outcomes Primary outcome: reduction of all-type vascular thromboembolism during the study
period. All-type vascular thromboembolism included DVT, PE, all arterial events (e.g.
cerebrovascular accident/myocardial infarction), and all visceral thromboembolic events
diagnosed on the basis of clinical symptomatology, post-mortem, or incidentally
Outcome data kindly provided by the authors: VTE
Notes Central venous access devices and inferior vena cava filters were not allowed
Funding: the Hull and East Yorkshire Hospitals National Health Service Trust; Pzer
provided a grant covering the cost of dalteparin; Lilly provided a grant covering the cost
of biostatistics
Disclosure of potential conflicts of interest: The lead author has received honoraria and
participated on advisory boards for Pfizer. Another author received travel expenses from
Pfizer. None of the other authors has any conflicting interests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised in the
facilities of the Postgraduate Medical In-
stitute in Hull with software developed by
York University” Allocation and stratifica-
tion were done through remote telephone
“block” randomisation (personal commu-
nication)
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Comment: performed centrally at the
Medical Institute in Hull for all of the 7
recruiting sites. Allocation and stratifica-
tion were done through remote telephone
“block” randomisation (personal commu-
nication)
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: open study (personal commu-
nication)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: For effectiveness and safety, 59
out of 60 (98.3%) were analysed in the
LMWH group, and 62 out of 63 (98.4%)
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were analysed in the control group
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults section
Maurer 1997
Methods Multicentre RCT; intention-to-treat analyses not reported
Participants Patients with limited-stage small cell lung cancer receiving chemotherapy and radiother-
apy. Patients 60 years of age or older: 57.6%; males: 64.8%; metastatic disease: none;
previous VTE: not reported
Interventions Intervention: warfarin 10 mg/day for the first 3 days and then at a dose to maintain the
prothrombin time between 1.4 and 1.6 times the local institutional control standards
Control: no warfarin
Warfarin was continued through the complete course of chemotherapy and radiation
therapy and stopped 3 weeks after the last cycle of chemotherapy. Warfarin was admin-
istered for a median of 112.5 days
Outcomes Primary: overall survival and cancer response to therapy
Secondary: failure-free survival, disease-free survival, patterns of relapse, toxicity
Notes Funding: grants from the National Cancer Institute, Bethesda, MD
Disclosure of potential conflicts of interest: not reported, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized to re-
ceive warfarin or no warfarin”
Comment: method of sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomized to re-
ceive warfarin or no warfarin”
Comment: method of allocation conceal-
ment not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Comment: It is not reported whether par-
ticipants, physicians, and outcome asses-
sors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Table 6 of the study full-text in-
dicates that not all randomised participants
were analysed, but the exact numbers were
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not reported
Selective reporting (reporting bias) Unclear risk Comment: Only the outcomes overall sur-
vival and complete tumour response were
specified in the methods section. All other
outcomes were addressed in the results sec-
tion only, including the survival analyses at
8 months, 2, 3, and 4 years. Only the 8
months’ analyses were reported to be ex-
ploratory
Mitchell 2003
Methods PARKAA study: multicentre, open, phase II RCT; per-protocol analysis
Participants Paediatric patients newly diagnosed with acute lymphoblastic leukaemia treated with L-
asparaginase and a functioning central venous line placed within 2 weeks of initiating
induction chemotherapy. Mean age: 3.8 years in antithrombin and 5.9 years in control;
female, n (%): 10 (40) in antithrombin and 23 (38.3) in control; previous VTE: not
reported
Interventions Intervention: Thrombate III, a sterile, lyophilised preparation of purified human an-
tithrombin manufactured and supplied by Bayer Corporation, USA. Antithrombin was
infused once weekly for 4 weeks to increase plasma concentrations of antithrombin to
approximately 3.0 U/mL but no more than 4.0 units/mL
Control: standard care
Outcomes Primary outcomes: clinically symptomatic or incidental thrombotic event in any location;
major and minor bleeding
Secondary outcomes: surrogate outcome for thrombotic events by measuring markers
of thrombin generation
Notes Participants did receive small amounts of UFH for prophylaxis of central venous line
blockage either by continuous infusion (1 to 3 U/mL) or intermittent flushes (50 to 100
U/mL up to 4 times per day) according to local standard of care
Funding: The study was supported by a grant from the Canadian Institutes of Health
Research and Bayer Inc
Disclosure of potential conflicts of interest: not reported, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed by
the pharmacist-on-call using a computer
generated random number list.”
Comment: adequate method of sequence
generation
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Allocation concealment (selection bias) Low risk Quote: “Investigators at participating cen-
tres were blinded to the randomisation
code and unaware of patient treatment al-
location until after patients had been ran-
domised.”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “The PARKAA study was an open,
randomised, multi-centre extended phase
II clinical study” and “The thrombotic
events outcomes were adjudicated centrally
by committees consisting of physicians
with appropriate expertise, who were not
involved with study patients’ care and were
blinded to treatment groups”
Comment: Participants and physicians
were not blinded, whereas outcome asses-
sors were
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For effectiveness and safety, 25
out of 37 (67.6%) were analysed in the an-
tithrombin group, and 60 out of 72 (83.
3%) were analysed in the control group
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults section
Palumbo 2011
Methods Randomised, open-label, multicentre study;modified intention-to-treat analysis, includ-
ing participant receiving at least 1 study dose
Participants Patients with previously untreated myeloma who received thalidomide-containing reg-
imens and had no clinical indication or contraindication for a specific antiplatelet or
anticoagulant therapy. Median age: aspirin 61 years (55 to 66), warfarin 60 years (54
to 66), heparin 62 years (55 to 66); male, n (%): 117 (53), 115 (52), and 130 (59),
respectively; previous VTE: none. Median follow-up time: 24.9 months
Interventions Intevention 1: aspirin (100 mg/d)
Intervention 2: low-dose warfarin (1.25 mg/d)
Intervention 3: LMWH (enoxaparin 40 mg/d)
Prophylaxis was administered during the 3 cycles of induction therapy in participants≤
65 years and during the first 6 cycles of induction therapy in participants > 65 years
Median treatment duration: 2.6 months for aspirin, 2.4 months for low-dose warfarin,
and 2.6 months for LMWH
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Outcomes Primary outcomes: a composite measure of a first episode of objectively confirmed symp-
tomatic DVT, PE, arterial thrombosis, acute myocardial infarction or stroke, or sudden,
otherwise-unexplained death during the first 6 months from random assignment
Secondary outcomes: each component of the composite primary endpoint; long-term
cumulative incidence of the primary endpoint; major and minor bleeding events; any
toxicity that required interruption of study prophylaxis
Notes The trial sampled participants from 2 distinct RCTs, of which participants who received
thalidomide-based regimens were eligible to the substudy randomising antithrombotic
prophylaxis treatments
Karnofsky performance status < 70%: aspirin 25%, warfarin 29%, heparin 30%
Funding: none reported
Disclosure of potential conflicts of interest: Several authors reported paid consultant or
advisory roles, honoraria, and research funds that were relevant to the subject matter
under consideration in their trial report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A simple random assignment se-
quence was generated by a centralized com-
puter”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “After registration in a centralized
database through the Internet and valida-
tion of eligibility, patients were randomly
allocated to treatments using an automated
assignment procedure concealed to the in-
vestigators”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “open-label”
Comment: This was an open-label study.
It is not reported whether outcomes were
assessed blindly
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For effectiveness and safety, 220
out of 224 (98.2%) in the aspirin group,
220 out of 222 (99.1%) in the warfarin
group, and 219 out of 221 (99.1%) in the
LMWH group were analysed. In addition,
1 participant was not randomised by “clin-
ician mistake”
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Palumbo 2011 (Continued)
Selective reporting (reporting bias) High risk Comment: The outcome “any toxicity that
required interruption of study prophylaxis”
was not reported in the final report
Pelzer 2015
Methods CONKO 004 trial: open-label, multicentre RCT; intention-to-treat and per-protocol
analyses
Participants Outpatients with histologically confirmed advanced pancreatic cancer treated with first-
line chemotherapy. Age, median (range): enoxaparin 62 (32 to 81) and control 63 (27
to 83); female, n (%): enoxaparin 69 (43) and control 58 (38); metastatic disease, n (%):
enoxaparin 119 (74) and control 118 (78); previous VTE: not reported. Median follow-
up: 30.4 weeks
Interventions Intervention: LMWH, enoxaparin (1 mg/kg once daily) for 3 months started simulta-
neously to palliative systemic chemotherapy
Control: no enoxaparin
Quote: “After 3 months of initial enoxaparin use at half the therapeutic dosage (time
point of primary end point), treatment was continued with a fixed dose of 40 mg daily
until disease progression”
Outcomes Primary outcome: symptomatic VTEs within 3 months after random assignment
Secondary outcomes: progression-free survival; overall survival; overall symptomatic
VTE after 6, 9, and 12 months; major bleeding
Additional outcomes reported in related references: incidental DVT during months 6,
9, and 12; toxicity of the therapeutic regimen; time to cancer progression; remission at
3, 6, 9, and 12 months; quality of life
Notes Funding, quote: “Supported by Charité-Forschungsförderung, Arbeitsgemeinschaft In-
ternistische Onkologie, Deutsche Krebsgesellschaft, Amgen, Eli Lilly, and sanofi-aventis,
which provided enoxaparin free of charge.”
Disclosure of potential conflicts of interest: Quote: “Employment or Leadership Position:
None Consultant or Advisory Role: Helmut Oettle, Celgene (C), Eli Lilly (C), Fresenius
(C);HannoRiess, sanofi-aventis (C) StockOwnership:NoneHonoraria:HelmutOettle,
Celgene; Hanno Riess, sanofi-aventis, Roche, Amgen, Bayer, Novartis, Eli Lilly Research
Funding: Helmut Oettle, Celgene, Eli Lilly Expert Testimony: None Patents, Royalties,
and Licenses: None Other Remuneration: Uwe Pelzer, sanofi-aventis, Roche, Eli Lilly,
Amgen; Jens M. Stieler, sanofi-aventis, Roche, Eli Lilly, Amgen”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-gen-
erated random numbers generated at the
study coordination center at the Charité-
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Universitätsmedizin Berlin”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “computer-gen-
erated random numbers generated at the
study coordination center at the Charité-
Universitätsmedizin Berlin”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “All symptomatic VTEs and ma-
jor hemorrhages were documented using
the serious adverse event form, centrally re-
viewed and evaluated by an independent,
blinded event review board”
Comment: open-label study, with blinded
outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All randomised participants
were included in the analysis
Selective reporting (reporting bias) High risk Comment: Some of the outcomes indi-
cated in the related reports or in the main
article (quality of life) are not reported
Perry 2010
Methods PRODIGE study: phase III, randomised, placebo-controlled trial; intention-to-treat
analysis
Participants Patients over 18 years of age with newly diagnosed, pathologically confirmed WHO
grade 3 or grade 4 glioma. Mean age: 57 years (30 to 81) in the dalteparin group and 55
years (26 to 77) in the placebo group; male, n (%): 61 (62) and 50 (57), respectively;
previous VTE: none
Interventions Intervention: LMWH, dalteparin (5000 IU sc, once daily)
Control: placebo
Study treatment was given for 6 months starting within the first month after surgery.
Participants were allowed to continue study medication for 12 months
Median treatment duration: 183 days for LMWH and 157 days for placebo
Outcomes Primary outcomes: objectively documented symptomatic DVT or PE occurring during
the 6 months postrandomisation
Secondary outcomes: major and all bleeding, quality of life, cognition assessments, and
death
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Perry 2010 (Continued)
Notes Funding: Pzer Inc, Ontario Clinical Oncology Group, Crolla Chair in Brain Tumour
Research
Disclosure of potential conflicts of interest: The lead author disclosed research support
(and funding) by Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “using a computer-generated ran-
domization list”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Consenting patients were ran-
domized by contacting the Ontario Clini-
cal Oncology Group (OCOG) Coordinat-
ing and Methods Centre at the Henderson
Research Centre”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “In our study, investigators, pa-
tients and outcome assessors were blinded
to treatment allocation. In addition, VTE
andbleeding outcomeswere adjudicated by
a central committee unaware of treatment
assignment.”
Comment: Participants, physicians, and
outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All randomised participants
were included in the analysis
Selective reporting (reporting bias) High risk Comment: The outcomes quality of life
and cognition assessment were mentioned
in the methods but not reported in the re-
sults
Sideras 2006
Methods Multicentre, placebo-controlled randomised study; type of analyses not reported
Participants Patients with advanced breast cancer who had failed first-line chemotherapy; advanced
prostate cancer who had failed primary hormonal therapy; advanced lung cancer; or
advanced colorectal cancer. Median age for blinded LMWH: 64.5 years; placebo: 63.5
years; unblinded LMWH: 68.5 years; standard care: 70.5 years
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Interventions First part of the study, double-blinded (52 participants):
LMWH, dalteparin (5000 IU sc, once daily) plus standard clinical care
Control: placebo (saline injections) plus standard clinical care
Second part of the study, open (86 participants):
LMWH, dalteparin (5000 IU sc, once daily) plus standard clinical care
Control: standard clinical care alone
Duration: 18 weeks or until disease progression
Outcomes Primary outcome: overall survival
Secondary outcomes: toxic effects, incidence of thromboembolic events, changes in
quality of life
Notes Funding: Public Health Services grants from the National Cancer Institute, Department
of Health and Human Services
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of random sequence
generation not reported
Allocation concealment (selection bias) Low risk Quote: “The randomization processes ap-
pliedwere handled through theNorthCen-
tral Cancer Treatment Group (NCCTG)
Randomization Office.”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: The study used a double-
blinded design in the first part of the trial,
and an open-label design in the second part
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For effectiveness and safety, 68
out of 69 participants (98.6%) were anal-
ysed in the LMWH group, and 70 out of
72 (97.2%) were analysed in the placebo
group
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion sections
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Vadhan-Raj 2013
Methods Randomised, open-label, parallel-group trial
Participants Patients 18 years or older with a diagnosis of advanced stage (unresectable or metastatic)
adenocarcinoma of the pancreas planning to initiate systemic chemotherapy within 2
weeks, ECOG performance status 0 to 2, adequate renal function (creatinine clearance
of > 50 mL/min). Median age 52 years (range 36 to 77 years); gender: 41 males and 34
females; previous VTE and metastatic disease: not reported
Interventions Intervention: LMWH, dalteparin (5000 IU sc, once daily) for 16 weeks during chemo-
therapy
Control: chemotherapy alone
Outcomes Primary outcome: venous thromboembolic events during 16 weeks of treatment
Other outcomes mentioned in the abstract: adverse events, clinically significant bleeding,
overall survival
Notes Funding: not reported
Disclosure of potential conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were randomized 1:1 to dalteparin
vs control arms”
Comment: method of sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Quote: “were randomized 1:1 to dalteparin
vs control arms”
Comment: method of allocation conceal-
ment not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: open-label study. It is not re-
ported in the abstract if outcome assessors
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All 75 patients were evaluable for
response in an intent-to-treat analysis”
Comment: All randomised participants
were included in the analysis
Selective reporting (reporting bias) Unclear risk Comment: It is not clear from the abstract
if all outcomes are reported
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van Doormaal 2011
Methods INPACT study: multicentre, open-label RCT; intention-to-treat analyses for mortality
Participants Patients with non-small cell lung cancer (stage IIIB), hormone-refractory prostate cancer,
or locally advanced pancreatic cancer. Age, mean (SD): 65 (10) years in the nadroparin
group and 65 (9.8) years in the no-nadroparin group;male, n (%): 197 (81) in nadroparin
and 206 (80) in no-nadroparin; metastatic disease in prostate cancer, n (%): 73 (73.7)
in nadroparin and 85 (87.6) in no-nadroparin; previous VTE: none. Median duration
of follow-up: 10.4 months
Interventions Intervention: LMWH, nadroparin in addition to standard anticancer treatment
Subcutaneous nadroparin was administered for 6 weeks (2 weeks at therapeutic dose and
4 weeks at half therapeutic dose). Participants were eligible to receive additional cycles of
nadroparin (2 weeks at therapeutic dose and 4 weeks of washout period) for a maximum
of 6 cycles
Mean duration of treatment: 12.6 weeks
Control: standard anticancer treatment
Outcomes Primary efficacy outcome: all-cause mortality
Primary safety outcome: major bleeding
Secondary efficacy outcomes: time to disease progression, clinically relevant non-major
bleeding, VTE, arterial thromboembolic events
Notes Funding: The study was supported by a grant from GlaxoSmithKline (Paris, France)
Disclosure of potential conflicts of interest: 2 authors reported consultant or advisory
roles, honoraria, and research funds that were relevant to the subject matter under con-
sideration in their trial report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Allocation of treatment proceeded
centrally by using an interactive-voice re-
sponse system”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Allocation of treatment proceeded
centrally by using an interactive-voice re-
sponse system”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “all study outcomes were adjudi-
cated by an independent, blinded commit-
tee”
Comment: open study with blinded out-
come assessors
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: For effectiveness and safety, the
overall percentage of participants enrolled
and subsequently excluded from the anal-
ysis was 2.2% (11/503)
Selective reporting (reporting bias) Low risk Comment: All outcomes reported in the
methods section were addressed in the re-
sults or discussion section
Zacharski 1981
Methods Veterans Administration Study No. 75: multicentre RCT, type of analyses not reported
Participants Patients with small cell lung carcinoma treated with chemotherapy and radiation therapy.
Males: 100%. Extensive cancer: 52% warfarin and 48% control group; previous VTE:
not reported
Interventions Intervention: warfarin at doses to prolong the prothrombin time to approximately 2
times the control value
Control: no warfarin
The median duration of warfarin administration was 27 weeks.
Outcomes Primary efficacy outcomes: survival and cancer response to treatment
Notes Funding: VA Cooperative Studies Program
Disclosure of potential conflicts of interest: not reported, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “subjected to computer randomiza-
tion”
Comment: adequate method of sequence
generation
Allocation concealment (selection bias) Low risk Quote: “subjected to computer randomiza-
tion”
Comment: adequate method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Comment: It is not reported whether par-
ticipants, physicians, and outcome asses-
sors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “No patient has been lost to follow-
up.”
Comment: All enrolled participants were
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included in the analysis
Selective reporting (reporting bias) Unclear risk Comment: Bleeding was addressed in the
results section, but not mentioned in the
methods section
Zwicker 2013
Methods MicroTEC study: randomised, multicentre phase II study; use of intention-to-treat
analyses reported
Participants Patients with histologically confirmed advanced-stage malignancy for which standard
curative therapies did not exist. Eligible malignancies included: adenocarcinoma of the
pancreas (locally advanced or metastatic), colorectal (stage IV), non-small cell lung can-
cer (stage III or IV), relapsed or stage IV ovarian, or surgically unresectable or metastatic
gastric adenocarcinoma. Median age was 68.1 years (46.6 to 80.1) in the LMWH group
and 67.5 years (28.8 to 78.7) in the observation group. Male sex: 61% and 46%, respec-
tively. Overall, 78.8% of the participants had metastatic disease; previous VTE: none
Interventions Intervention: LMWH, enoxaparin (40 mg sc, once daily)
Control: observation
Treatment was given for 2 months.
Outcomes Primary efficacy outcome: cumulative incidence of VTE (i.e. any symptomatic proximal
or distal lower extremity DVT, incidental proximal DVT, symptomatic PE, or fatal PE)
at 2 months
Primary safety outcome: major bleeding
Secondary: toxicity and survival
Notes Funding, quote: “the study was supported by grants from the National Institutes of
Health, K23 HL84052 (JIZ) and R01 HL095084 (BF), as well as a research grant from
Sano”
Disclosure of potential conflicts of interest: 1 author has served on steering committees
for Sanofi, and another has received research funds and served on advisory boards for
Sanofi and Eisai
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were randomized (2:1) to enoxa-
parin 40 mg subcutaneously once daily or
observation.”
Comment: method of sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Quote: “Study coordination, randomiza-
tion, and monitoring were performed by
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Zwicker 2013 (Continued)
the Quality Assurance Office for Clini-
cal Trials (QACT) at Dana Farber/Harvard
Cancer Center.”
Comment: method of allocation conceal-
ment not clearly specified
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: Both the treating physicians
and participants in the observation arms
were blinded to microparticle status. How-
ever, participants in the control group were
only observed; the use of placebo, blinding
method, or an independent and blinded
adjudication committee was not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All randomised participants
were included in the analysis. 4 of the
70 participants initially enrolled were ex-
cluded prior to randomisation
Selective reporting (reporting bias) High risk Comment: The outcome toxicity was not
reported in the results section
COI: conflict of interest
CT: chemotherapy
DVT: deep vein thrombosis
ECOG: Eastern Cooperative Oncology Group
INR: international normalised ratio
IQR: interquartile range
LMWH: low molecular weight heparin
PE: pulmonary embolism
RCT: randomised controlled trial
sc: subcutaneous
SD: standard deviation
UFH: unfractionated heparin
uLMWH: ultra-low molecular weight heparin
VTE: venous thromboembolism
WHO: World Health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baz 2005 Not an RCT
Bergqvist 1983 Perioperative thromboprophylaxis
Bocharov 2011 Not an RCT and study includes surgical patients
Eichinger 2008 Inadequate population: hospitalised cancer patients
Gercor 2013 Study terminated. No published data available and results not reported in ClinicalTrials.gov
Haas 2011 Inadequate population: hospitalised cancer patients
Heilmann 1995 Perioperative thromboprophylaxis
Hills 1972 Perioperative thromboprophylaxis
Kessler 2011 Not an RCT
Kwaan 2007 Prophylaxis for catheter-related thrombosis
Levin 2008 Study was terminated early because of a drug supply issue. Results of a single participant are posted (accessed at
clinicaltrials.gov/ct2/show/results/NCT00790452 on 11 December 2012)
Macintyre 1974 Perioperative thromboprophylaxis
Maxwell 2000 Perioperative thromboprophylaxis
Meister 2008 Not an RCT
Minnema 2004 Not an RCT
Niesvizky 2007 Inadequate type of intervention: antiplatelet agent versus placebo
Pandya 2002 Study was terminated early, and no results were posted on ClinicalTrials.gov (accessed at clinicaltrials.gov/ct2/
show/NCT00031837 on 13 June 2013)
Paydas 2008 Not an RCT
Poniewierski 1987 Inadequate population: hospitalised cancer patients
Rajan 1995 Inadequate outcomes
Sideras 2007 Perioperative thromboprophylaxis
Weber 2008 Inadequate population: hospitalised cancer patients
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Welti 1981 Perioperative thromboprophylaxis
Zangari 2003 Not an RCT
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Ciftci 2012
Methods Single-centre, randomised study
Participants Patients with lung cancer
Interventions Intervention: warfarin in addition to standard anticancer treatment. Warfarin was given orally for 6 months starting
on day 1 of chemotherapy at a dose of 5 mg/d to achieve a target international normalised ratio of 1.5 to 2.5
Control: standard anticancer treatment
Outcomes No clear distinction between primary and secondary outcomes. Outcomes reported in the abstract: overall median
survival, response rates (complete + partial), bleeding
Notes
NCT00771563
Methods Open-label RCT
Participants Patients with locally advanced or metastatic non-small cell lung cancer (stage IIIB or IV) who were not candidates
for radical combined-modality treatments or high-dose radiation therapy
Interventions Intervention: chemotherapy (cisplatin + docetaxel) and enoxaparin 1 mg/kg/day sc
Control: chemotherapy (cisplatin + docetaxel)
Outcomes Primary outcome: progression-free survival
Secondary outcomes: symptom control evaluated with the Lung Cancer Symptoms Scale, overall survival, best overall
response, incidence of total documented thromboembolic and haemorrhagic events, overall safety and tolerability
Notes ClinicalTrials.gov identifier: NCT00771563
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Salat 1990
Methods Prospective RCT
Participants Patients (n = 80) with malignant diseases
Interventions Intervention: unfractionated heparin (2 x 7500 IU/mL)
Control: low molecular weight heparin, dalteparin (5000 IU sc, once daily)
Outcomes Thrombosis and haemorrhagic complications
Notes
RCT: randomised controlled trial
sc: subcutaneous
Characteristics of ongoing studies [ordered by study ID]
NCT00662688
Trial name or title Chemotherapy with or without preventive anticoagulation for metastatic cancer of the pancreas
Methods Randomised, multicentre study. Methods of randomisation and allocation concealment unclear
Participants Patients with histologically confirmed adenocarcinoma of the pancreas (metastatic disease, not amenable
to treatment, no localised or locally advanced disease) receiving treatment with different combinations of
gemcitabine and capecitabine
Interventions Arm 1A: gemcitabine hydrochloride IV over 150 minutes on days 1 and 15
Arm 1B: gemcitabine hydrochloride as in arm 1A and LMWH, dalteparin sc on day 1
Arm 2A: gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and oral capecitabine every 12
hours on days 1 to 21
Arm 2B: gemcitabine hydrochloride and capecitabine as in arm 2A and LMWH, dalteparin sc as in arm 1B
Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity
Outcomes Primary outcome measures: thromboembolic events
Secondary outcome measures: thromboembolic-related survival, progression-free survival, overall survival,
time to response of tumour, tolerance of regimens
Starting date October 2007
Contact information Chibauldel B
Notes NCT00662688
Note: The study status in ClinicalTrials.gov is “terminated”
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NCT00717938
Trial name or title A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer
Methods Open-label RCT
Participants Patients with histologically or cytologically verified small cell lung cancer, all stages
Interventions Intervention: cisplatinum or carboplatin and e.g. etoposide + enoxaparin
Control: cisplatinum or carboplatin and e.g. etoposide
Outcomes Primary outcome: overall survival
Secondary outcome: toxicity
Starting date June 2008
Contact information Lars Ek, lars.ek@skane.se
Notes ClinicalTrials.gov identifier: NCT00717938
NCT00718354
Trial name or title Randomized, phase III-b, multi-centre, open-label, parallel study of enoxaparin (low molecular weight hep-
arin) given concomitantly with chemotherapy vs chemotherapy alone in patients with inoperable gastric and
gastro-oesophageal cancer
Methods Randomised, open-label, multicentre study. Methods of randomisation and allocation concealment unclear
Participants Patients with inoperable (locally advanced) or metastatic newly diagnosed gastric or gastro-oesophageal cancer
Interventions Intervention: LMWH, enoxaparin (1 mg/kg sc once daily) in addition to standard chemotherapy up to 6
months
Control: standard chemotherapy (up to 6 cycles)
Outcomes Primary outcome measures: event-free survival (composite endpoint of overall survival plus free of symp-
tomatic VTE)
Secondary outcome measures: incidence of symptomatic VTE, overall survival, major and minor bleeding
during chemotherapy and/or up to 30 days after last dose is provided, serious adverse events, all reported
adverse events, HIT
Starting date July 2008
Contact information Maganji JM, mmaganji@tri-london.ac.uk
Notes NCT00718354
Note: Study status in ClinicalTrials.gov is “complete”.
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NCT02048865
Trial name or title Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients: a random-
ized placebo-controlled, double-blind clinical trial
Methods Double-blind (participant, caregiver, investigator, outcomes assessor), parallel-assignment RCT
Participants Patients with a newly diagnosed cancer site or progression of the malignant disease after complete or partial
remission who are initiating a new course of chemotherapy with a minimum intent of 3 months’ therapy and
who have a VTE risk stratification score of ≥ 2, according to the scoring method
Interventions Intevention: apixaban 2.5 mg twice daily for 6 months
Control: placebo drug
Outcomes Primary outcome: symptomatic or incidental VTE (DVT or PE, or both)
Secondary outcomes: rate of adverse events, clinical overt bleeding (major and minor bleeding), and death
within the study period
Starting date January 2014
Contact information Marc Carrier, mcarrier@toh.on.ca
Notes ClinicalTrials.gov identifier: NCT02048865
NCT02285738
Trial name or title Anti-platelet and statin therapy to prevent cancer-associated thrombosis: a pilot study
Methods Open-label, parallel-assignment RCT
Participants Patients with a histologic diagnosis of malignancy of a solid organ or lymphoma who have a VTE risk score
of 1 or higher and will be initiating a new systemic chemotherapy regimen
Interventions Intervention 1: aspirin
Intervention 2: simvastatin
Control: observation
Outcomes Primary outcome: change in average sP-selectin levels
Secondary outcomes: major bleeding complications or clinically significant non-bleeding complications,
change in circulating biomarkers, thrombotic events including venus thrombosis, pulmonary embolism,
visceral vein thrombosis as well as arterial thromboembolic events including stroke, myocardial infarction, or
arterial embolism
Starting date December 2014
Contact information
Notes ClinicalTrials.gov identifier: NCT02285738
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NCT02555878
Trial name or title Efficacy and safety of rivaroxaban prophylaxis compared with placebo in ambulatory cancer patients initiating
systemic cancer therapy and at high risk for venous thromboembolism
Methods Multicentre, randomised, double-blind (participant, caregiver, investigator), placebo-controlled, parallel-
group superiority study
Participants Patients with histologically confirmed solid malignancy including but not limited to: pancreas, lung, stomach,
colon, rectum, bladder, breast, ovary, renal, or lymphoma (haematologic), with locally advanced or metastatic
disease who have a Khorana thromboembolic risk score ≥ 2
Interventions Intervention: rivaroxaban 10 mg tablet orally once daily for 180 days
Control: placebo
Outcomes Primary efficacy outcome: symptomatic and incidental lower extremity proximal DVT, symptomatic upper
extremity DVT, symptomatic non-fatal PE, incidental PE, VTE-related death
Primary safety outcome: major bleeding
Secondary outcomes: symptomatic VTE and VTE-related deaths, all-cause mortality, clinically relevant non-
major bleeding, minor bleeding, any bleeding adverse events, and serious adverse events
Starting date September 2015
Contact information Janssen Research & Development, LLC Clinical Trial
Notes ClinicalTrials.gov identifier: NCT02555878
DVT: deep vein thrombosis
HIT: heparin-induced thrombocytopenia
IV: intravenous
LMWH: low molecular weight heparin
PE: pulmonary embolism
RCT: randomised controlled trial
sc: subcutaneous
VTE: venous thromboembolism
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D A T A A N D A N A L Y S E S
Comparison 1. Anticoagulants versus control: symptomatic venous thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Symptomatic VTE: LMWH vs
no thromboprophylaxis
9 3284 Risk Ratio (IV, Random, 95% CI) 0.54 [0.38, 0.75]
2.1 Dalteparin 5 901 Risk Ratio (IV, Random, 95% CI) 0.64 [0.39, 1.06]
2.2 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.57 [0.24, 1.35]
2.3 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.50 [0.22, 1.13]
2.4 Enoxaparin 1 312 Risk Ratio (IV, Random, 95% CI) 0.43 [0.21, 0.88]
2.5 Bemiparin 1 38 Risk Ratio (IV, Random, 95% CI) 0.10 [0.01, 1.75]
3 Symptomatic VTE: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.51 [0.22, 1.17]
4 Symptomatic VTE: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic VTE: prophylactic
vs intermediate or therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
5.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 2.89 [0.12, 67.75]
5.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 1.0 [0.07, 15.15]
6 Symptomatic VTE: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
7 Symptomatic VTE: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
8 Symptomatic VTE: apixaban vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Anticoagulants versus control: major bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major bleeding: semuloparin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Major bleeding: LMWH vs no
thromboprophylaxis
13 6356 Risk Ratio (IV, Random, 95% CI) 1.44 [0.98, 2.11]
2.1 Dalteparin 6 3119 Risk Ratio (IV, Random, 95% CI) 1.29 [0.67, 2.47]
2.2 Certoparin 1 898 Risk Ratio (IV, Random, 95% CI) 2.19 [0.84, 5.70]
2.3 Nadroparin 3 1955 Risk Ratio (IV, Random, 95% CI) 1.83 [0.69, 4.85]
2.4 Enoxaparin 2 346 Risk Ratio (IV, Random, 95% CI) 1.24 [0.56, 2.73]
2.5 Bemiparin 1 38 Risk Ratio (IV, Random, 95% CI) 0.30 [0.01, 6.97]
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3 Major bleeding: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.14 [0.01, 2.76]
4 Major bleeding: LMWH vs
warfarin
1 440 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Major bleeding: prophylactic
vs intermediate or therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
5.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Major bleeding: vitamin
K antagonists vs no
thromboprophylaxis
4 994 Risk Ratio (IV, Random, 95% CI) 3.82 [0.97, 15.04]
7 Major bleeding: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
8 Major bleeding: antithrombin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
9 Major bleeding: apixaban vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Anticoagulants versus control: symptomatic pulmonary embolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic PE: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Symptomatic PE: LMWH vs no
thromboprophylaxis
7 5226 Risk Ratio (IV, Random, 95% CI) 0.59 [0.40, 0.86]
2.1 Dalteparin 4 2881 Risk Ratio (IV, Random, 95% CI) 0.61 [0.40, 0.92]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.50 [0.10, 2.44]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.60 [0.14, 2.49]
2.4 Enoxaparin 1 312 Risk Ratio (IV, Random, 95% CI) 0.14 [0.01, 2.61]
3 Symptomatic PE: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.13 [0.02, 1.03]
4 Symptomatic PE: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic PE: prophylactic
vs intermediate or therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
5.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 2.89 [0.12, 67.75]
5.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 3.0 [0.13, 70.42]
6 Symptomatic PE: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
7 Symptomatic PE: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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8 Symptomatic PE: apixaban vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Anticoagulants versus control: symptomatic deep vein thrombosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic DVT: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Symptomatic DVT: LMWH vs
no thromboprophylaxis
8 5310 Risk Ratio (IV, Random, 95% CI) 0.49 [0.35, 0.67]
2.1 Dalteparin 5 2965 Risk Ratio (IV, Random, 95% CI) 0.50 [0.32, 0.78]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.50 [0.19, 1.31]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.46 [0.18, 1.20]
2.4 Enoxaparin 1 312 Risk Ratio (IV, Random, 95% CI) 0.45 [0.22, 0.93]
3 Symptomatic DVT: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.81 [0.32, 2.04]
4 Symptomatic DVT: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic DVT: prophylactic
vs intermediate or therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
5.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 0.33 [0.01, 7.82]
6 Symptomatic DVT: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
7 Symptomatic DVT: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
8 Symptomatic DVT: apixaban vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 5. Anticoagulants versus control: incidental venous thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidental VTE: semuloparin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Incidental VTE: LMWH vs no
thromboprophylaxis
4 4354 Risk Ratio (IV, Random, 95% CI) 0.66 [0.41, 1.08]
2.1 Dalteparin 2 2321 Risk Ratio (IV, Random, 95% CI) 0.62 [0.33, 1.14]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.74 [0.21, 2.62]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.75 [0.26, 2.14]
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3 Incidental VTE: prophylactic
vs intermediate or therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
3.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 2.89 [0.12, 67.75]
3.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 3.0 [0.13, 70.42]
Comparison 6. Anticoagulants versus control: overall venous thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall VTE: semuloparin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Overall VTE: LMWH vs no
thromboprophylaxis
9 5366 Risk Ratio (IV, Random, 95% CI) 0.59 [0.48, 0.73]
2.1 Dalteparin 4 2494 Risk Ratio (IV, Random, 95% CI) 0.54 [0.41, 0.70]
2.2 Nadroparin 3 1955 Risk Ratio (IV, Random, 95% CI) 0.78 [0.48, 1.27]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.65 [0.37, 1.15]
2.4 Enoxaparin 1 34 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.36]
3 Overall VTE: prophylactic vs
intermediate vs therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
3.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 4.81 [0.24, 95.58]
3.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 5.0 [0.25, 99.34]
4 Overall VTE: antithrombin vs
placebo
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 7. Anticoagulants versus control: clinically relevant bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinically relevant bleeding:
semuloparin vs placebo
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Clinically relevant
bleeding: LMWH vs no
thromboprophylaxis
4 3105 Risk Ratio (IV, Random, 95% CI) 3.40 [1.20, 9.63]
3 Clinically relevant bleeding:
prophylactic vs intermediate vs
therapeutic LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
3.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 0.33 [0.01, 7.82]
4 Clinically relevant bleeding:
apixaban vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
103Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 Clinically relevant
bleeding: UFH vs no
thromboprophylaxis
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 8. Anticoagulants versus control: minor bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Minor bleeding: LMWH vs no
thromboprophylaxis
7 2803 Risk Ratio (IV, Random, 95% CI) 1.23 [0.89, 1.70]
1.1 Dalteparin 4 717 Risk Ratio (IV, Random, 95% CI) 1.25 [0.72, 2.17]
1.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 1.00 [0.69, 1.45]
1.3 Certoparin 1 898 Risk Ratio (IV, Random, 95% CI) 1.96 [1.11, 3.46]
1.4 Bemiparin 1 38 Risk Ratio (IV, Random, 95% CI) 0.45 [0.09, 2.17]
2 Minor bleeding: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.70 [0.17, 2.84]
3 Minor bleeding: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Minor bleeding: prophylactic
vs intermediate or therapeutic
LMWH
1 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
4.1 Prophylactic vs
intermediate
1 51 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Prophylactic vs therapeutic 1 52 Risk Ratio (IV, Fixed, 95% CI) 0.2 [0.01, 3.97]
5 Minor bleeding: UFH vs no
thromboprophylaxis
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
6 Minor bleeding: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
7 Minor bleeding: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
8 Minor bleeding: antithrombin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 9. Anticoagulants versus control: 1-year mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 1-year mortality: semuloparin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 1-year mortality: LMWH vs no
thromboprophylaxis
8 2304 Risk Ratio (IV, Random, 95% CI) 0.93 [0.80, 1.09]
2.1 Dalteparin 4 782 Risk Ratio (IV, Random, 95% CI) 0.97 [0.77, 1.21]
2.2 Nadroparin 2 1452 Risk Ratio (IV, Random, 95% CI) 0.95 [0.77, 1.18]
2.3 Enoxaparin 1 34 Risk Ratio (IV, Random, 95% CI) 0.72 [0.34, 1.51]
2.4 Bemiparin 1 36 Risk Ratio (IV, Random, 95% CI) 0.18 [0.05, 0.70]
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3 1-year mortality: UFH vs no
thromboprophylaxis
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 10. Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic arterial
thromboembolism: LMWH vs
no thromboprophylaxis
4 3974 Risk Ratio (IV, Random, 95% CI) 0.74 [0.46, 1.18]
1.1 Dalteparin 2 2321 Risk Ratio (IV, Random, 95% CI) 0.90 [0.52, 1.53]
1.2 Nadroparin 2 1653 Risk Ratio (IV, Random, 95% CI) 0.38 [0.14, 1.03]
2 Symptomatic arterial
thromboembolism: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 2.01 [0.37, 10.86]
3 Symptomatic arterial
thromboembolism: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Symptomatic arterial
thromboembolism: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic arterial
thromboembolism: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 11. Anticoagulants versus control: superficial venous thrombosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Superficial venous
thrombosis: LMWH vs no
thromboprophylaxis
2 2033 Risk Ratio (IV, Random, 95% CI) 0.83 [0.30, 2.26]
1.1 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.83 [0.30, 2.26]
2 Superficial venous thrombosis:
LMWH vs aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Comparison 12. Anticoagulants versus control: serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events:
semuloparin vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Serious adverse events: LMWH
vs no thromboprophylaxis
5 1531 Risk Ratio (IV, Random, 95% CI) 0.86 [0.70, 1.07]
2.1 Dalteparin 3 343 Risk Ratio (IV, Random, 95% CI) 1.22 [0.45, 3.34]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.89 [0.68, 1.17]
2.3 Bemiparin 1 38 Risk Ratio (IV, Random, 95% CI) 0.75 [0.43, 1.30]
3 Serious adverse events: apixaban
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. Results of stratified analyses on symptomatic venous thromboembolism
Variable N of trials N of participants
(LMWH)
N of participants
(control)
RR (95% CI) Heterogeneity
I2/Tau2
P for interaction
All trials 9 1849 1435 0.54 (0.38 to 0.
75)
0.0/0.00
Type of LMWH 0.710
Dalteparin 5 458 443 0.64 (0.39 to 1.
06)
0.0/0.00
Certoparin 1 442 441 0.57 (0.24 to 1.
35)
NA
Nadroparin 1 769 381 0.50 (0.22 to 1.
13)
NA
Enoxaparin 1 160 152 0.43 (0.21 to 0.
88)
NA
Bemiparin 1 20 18 0.10 (0.01 to 1.
75)
NA
Type of dosage 0.322
Prophylactic 7 1630 1223 0.61 (0.41 to 0.
92)
0.0/0.00
Higher than pro-
phylactic
2 219 212 0.41 (0.23 to 0.
75)
0.0/0.00
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Table 1. Results of stratified analyses on symptomatic venous thromboembolism (Continued)
Type of cancer 0.610
Mixed 3 828 555 0.70 (0.33 to 1.
51)
0.0/0.00
Lung 4 529 404 0.40 (0.20 to 0.
80)
0.0/0.00
Pancreatic 2 219 212 0.41 (0.23 to 0.
75)
0.0/0.00
Glioma 1 99 87 0.74 (0.35 to 1.
57)
NA
Breast cancer 1 174 177 0.76 (0.17 to 3.
36)
NA
Allocation con-
cealment
0.960
Adequate 7 1365 952 0.54 (0.37 to 0.
78)
0.0/0.00
Inadequate or
unclear
2 484 483 0.55 (0.24 to 1.
26)
0.0/0.00
Blinding of par-
ticipants
0.353
Double-blind 4 1500 1093 0.62 (0.40 to 0.
96)
0.0/0.00
Inadequate or
unclear blinding
5 349 342 0.44 (0.26 to 0.
74)
0.0/0.00
Intention-to-
treat analysis
0.627
Yes 4 338 317 0.50 (0.31 to 0.
79)
0.0/0.00
No or unclear 5 1511 1118 0.59 (0.36 to 0.
97)
0.0/0.00
Selective out-
come reporting
0.857
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Table 1. Results of stratified analyses on symptomatic venous thromboembolism (Continued)
Adequate 7 1590 1196 0.52 (0.34 to 0.
82)
0.0/0.00
Incomplete or
unclear
2 259 239 0.56 (0.33 to 0.
95)
5.6/0.01
CI: confidence interval
LMWH: low molecular weight heparin
NA: not applicable, only 1 trial contributing to this stratum
RR: risk ratio
Table 2. Results of stratified analyses on major bleeding
Variable N of trials N of participants
(LMWH)
N of participants
(control)
RR (95% CI) Heterogeneity
I2/Tau2
P for interaction
All trials 12* 3378 2978 1.44 (0.98 to 2.
11)
0.0/0.00
Type of LMWH 0.736
Dalteparin 6 1567 1552 1.29 (0.67 to 2.
47)
0.0/0.00
Certoparin 1 447 451 2.19 (0.84 to 5.
70)
NA
Nadroparin 3 1161 794 1.83 (0.69 to 4.
85)
13.8/0.15
Enoxaparin 2 183 163 1.24 (0.56 to 2.
73)
NA
Bemiparin 1 20 18 0.30 (0.01 to 6.
97)
NA
Type of dosage 0.669
Prophylactic 8 2744 2340 1.56 (0.91 to 2.
69)
0.0/0.00
Higher than pro-
phylactic
4 611 627 1.32 (0.76 to 2.
27)
0.0/0.00
Type of cancer 0.641
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Table 2. Results of stratified analyses on major bleeding (Continued)
Mixed 6 1293 1027 1.24 (0.63 to 2.
42)
0.0/0.00
Lung 4 1593 1472 1.49 (0.79 to 2.
80)
0.0/0.00
Pancreatic 2 219 214 1.21 (0.58 to 2.
51)
0.0/0.00
Glioma 1 99 87 4.39 (0.52 to 36.
89)
NA
Breast cancer 1 174 178 7.16 (0.37 to 137.
60)
NA
Definition of
major bleeding
0.235
Standard** 9 3077 2697 1.70 (1.07 to 2.
70)
0.0/0.00
Alternative or
unclear
3 278 270 0.99 (0.50 to 1.
98)
0.0/0.00
Trial size 0.917
Large 1 1101 1101 1.50 (0.62 to 3.
66)
NA
Small 11 2254 1866 1.42 (0.93 to 2.
18)
0.0/0.00
Allocation con-
cealment
0.447
Adequate 10 2858 2468 1.33 (0.87 to 2.
04)
0.0/0.00
Inadequate or
unclear
2 497 499 2.00 (0.81 to 4.
94)
0.0/0.00
Blinding of par-
ticipants
0.175
Double-blind 6 1897 1516 1.97 (1.11 to 3.
51)
0.0/0.00
Inadequate or
unclear blinding
6 1458 1451 1.11 (0.66 to 1.
86)
0.0/0.00
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Table 2. Results of stratified analyses on major bleeding (Continued)
Intention-to-
treat analysis
0.941
Yes 7 1637 1622 1.45 (0.87 to 2.
43)
0.0/0.00
No or unclear 5 1718 1345 1.41 (0.76 to 2.
61)
6.0/0.03
Selective out-
come reporting
0.989
Adequate 10 3096 2728 1.43 (0.91 to 2.
25)
0.0/0.00
Incomplete or
unclear
2 259 239 1.56 (0.59 to 4.
11)
16.7/0.13
CI: confidence interval
LMWH: low molecular weight heparin
NA: not applicable, only 1 trial contributing to this stratum
RR: risk ratio
*Zwicker 2013, who reported 0 events in both the LMWH and control group, was excluded from all analyses.
**The definition of major bleeding was considered ’standard’ when it matched the definition of the International Society of Thrombosis
and Haemostasis (Schulman 2005).
WH A T ’ S N E W
Last assessed as up-to-date: 23 June 2016.
Date Event Description
9 July 2016 New citation required but conclusions have not changed Searches rerun. Five additional studies were added to the
included studies. Two additional studies excluded on full-
text basis. New authors joined the review team. ’Summary
of findings’ tables added. Conclusions not changed
9 July 2016 New search has been performed Searches rerun. Five additional studies were added to the
included studies. Two additional studies excluded on full-
text basis
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H I S T O R Y
Protocol first published: Issue 5, 2010
Review first published: Issue 2, 2012
Date Event Description
24 July 2013 New citation required but conclusions have not changed Searches rerun. Twelve additional studies were added to
the included studies and nine additional studies to the
excluded studies. Risk of bias was reassessed in all included
trials. Conclusions not changed. Change in author team
24 July 2013 New search has been performed Searches rerun. Twelve additional studies were added to
the included studies and nine additional studies to the
excluded studies
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this update, we added clinically relevant bleeding to the safety outcomes. Clinically relevant bleeding, which is the composite of
major and clinically relevant non-major bleeding, has a significant impact on cancer patients’ morbidity and has been reported more
consistently in recent studies.
The protocol specified that we would evaluate heterogeneity in results between trials with the I2 statistic (Higgins 2003; Rücker 2008).
However, we added the variance estimate Tau2 to indicate and interpret heterogeneity, as currently advised by the Cochrane Handbook
for Systematic reviews of Interventions (Higgins 2011).
For the comparison of LMWH versus no thromboprophylaxis, we could not perform stratified analyses of the main outcomes by
age, stage of cancer (metastatic versus non-metastatic), and differences in the use of co-interventions in the trial groups due to poor
reporting or lack of contrast (age). Reported mean age at study entry was 65 years or younger in all studies on LMWH except for
Zwicker 2013, which included participants with a mean age above 65. Although we were unable to analyse dosage as a continuous
variable, we could stratify the analyses according to trials using prophylactic dosage versus those using other (higher than prophylactic)
dosages. In addition, we could not stratify by trial size for the outcome symptomatic VTE, as none of the trials reporting this outcome
was considered large. In the previous versions of this review, we defined large trials as those randomising at least 1450 participants. This
number was informed by a sample size calculation, assuming a symptomatic VTE rate of 2.7% in the LMWH group and 5.8% in the
non-active control group, a power of 80%, and a two-sided alpha of 0.05. In this version of the review, we used a slightly lower threshold
of 1360 to define large trials, using the event rate of 7.1% as suggested by Khorana 2008 for the control event rate (see Methods). The
change in threshold did not affect the classification in large versus small trials. We could not use the uni-variable random-effects meta-
regression model by dosage of intervention.
We planned to perform meta-regression on both treatment duration and follow-up duration. The treatment duration equaled the
follow-up duration in all studies except the one by Pelzer and colleagues (Pelzer 2015), which added one month of follow-up after the
end of treatment. We therefore only analysed the effect of treatment duration on major bleeding and symptomatic VTE. In all other
comparisons, no exploration of the effects of participant or trial characteristics on symptomatic VTE or major bleeding could be done
due to the low number of studies identified.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Ambulatory Care; Anticoagulants [adverse effects; ∗therapeutic use]; Antineoplastic Agents [adverse effects]; Antithrombins [thera-
peutic use]; Hemorrhage [chemically induced]; Heparin [adverse effects; therapeutic use]; Heparin, Low-Molecular-Weight [adverse
effects; therapeutic use]; Neoplasms [complications; ∗drug therapy]; Pulmonary Embolism [etiology; prevention & control]; Random-
ized Controlled Trials as Topic; Venous Thromboembolism [etiology; ∗prevention & control]; Warfarin [adverse effects; therapeutic
use]
MeSH check words
Adult; Child; Humans
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